Document:

<Page>

                                                                   Exhibit 10.10

                                LICENSE AGREEMENT

     This License Agreement ("AGREEMENT") is made as of this 13th day of
December, 2004 (the "EFFECTIVE DATE"), by and between ABBOTT LABORATORIES, an
Illinois corporation, with its principal office at 100 Abbott Park Road, Abbott
Park, Illinois 60064 ("ABBOTT"), and ADVANCED LIFE SCIENCES HOLDINGS, INC., a
Delaware corporation, with its principal office at 1440 Davey Road, Woodridge,
Illinois 60517 ("ALS").

                                   WITNESSETH

     WHEREAS, Abbott is the holder of certain patent applications and patents
("PATENTS," as more fully defined below) relating to the Compounds (as defined
below);

     WHEREAS, Abbott also possesses Know-How (as defined below) relating to the
Compounds; and

     WHEREAS, ALS wishes to obtain, and Abbott wishes to grant to ALS, an
exclusive license in the Territory (as defined below) under Abbott's Technology
(as defined below) for the development, manufacture and commercialization of
Products for Pharmaceutical Uses (as defined below).

     NOW THEREFORE, in consideration of the mutual obligations and promises as
set forth herein, the parties do hereby agree as follows:

     1.   DEFINITIONS. As used in this Agreement, the following terms shall have
the following respective meanings:

          1.1     "ABBOTT TECHNOLOGY" means the Patents and Know-How.

          1.2     "AFFILIATE" means any corporation, company, partnership, joint
venture and/or other entity which controls, is controlled by, or is under common
control of either party hereto. For purposes of this definition, control shall
mean direct or indirect ownership of more than fifty percent (50%) of the stock
or participating shares entitled to vote for the election of directors (but only
as long as such ownership exists).

          1.3     "COMPOUND A" means the compound known as ABT-773, its
enantiomers, racemates, isomers and any pharmaceutically acceptable salt or
complex thereof, in its current and any other formulation, and including any
Prodrugs and active metabolites, whether made before or after the Effective
Date.

          1.4     "COMPOUND B" means the compound known as ABT-210, its
enantiomers, racemates, isomers and any pharmaceutically acceptable salt or
complex thereof, in its current and any other formulation, and including any
Prodrugs and active metabolites, whether made before or after the Effective
Date.

          1.5     "COMPOUNDS" shall mean Compound A and Compound B,
collectively.

<Page>

          1.6     "CONFIDENTIAL INFORMATION" means any and all information or
data relating to either Compound A or Compound B and/or Product which, in the
course of carrying out a provision of this Agreement, a party discloses to the
other party, its employees or representatives, whether in writing, orally or by
observation, including, without limitation, all scientific, clinical, technical,
commercial, financial and business information and Know-How, and other
information or data considered confidential in nature. Subject to SECTION 7.1
hereof, Abbott shall hold in confidence and shall not directly or indirectly
disclose or provide to any third party Confidential Information pertaining to
Compound A, Compound B or Abbott Technology without ALS's prior written consent.
Confidential Information shall not include information or any portion thereof
which:

                  (a)   is known to the receiving party at the time of
                        disclosure hereunder and documented by written records
                        made prior to the date of such disclosure;

                  (b)   is subsequently disclosed to the receiving party by an
                        unaffiliated third person who has the right to make such
                        disclosure;

                  (c)   becomes patented, published or otherwise part of the
                        public domain other than through the acts of the
                        receiving party; or

                  (d)   is independently developed by or for the receiving party
                        by person(s) having no knowledge of such information as
                        evidenced by its written records.

          1.7     "EFFECTIVE DATE" shall have the meaning ascribed to such term
in the opening paragraph of this Agreement.

          1.8     "EXCLUSIVE LICENSE" means a license that operates to exclude
all others, including Abbott.

          1.9     "FIRST COMMERCIAL SALE" means the first sale of Product in the
Territory, after Regulatory Approval, by ALS or its Affiliates (or their
sublicensee(s)) to any unaffiliated third party as evidenced by the selling
party's invoice or other relevant document provided to such third party. A sale
to an unaffiliated third party shall not include quantities delivered solely for
research purposes, for clinical trials or quantities distributed as free samples
or promotions.

          1.10    "KNOW-HOW" means any proprietary technology, information,
methods of use, processes, techniques, ideas or inventions (other than the
Patents) owned, possessed or used by Abbott as of the Effective Date which is
directly related to or directly used in connection with Compound A or Compound B
or the manufacture of Compound A, Compound B and/or Product, including all trade
secrets and any other technical information relating to development, use or sale
of Compound A, Compound B and/or Product, provided that Abbott has the right to
license and/or sublicense to ALS. To the extent that any such Know-How relates
to other compounds in addition to Compound A and/or Compound B, Know-How shall
only include that portion of the Know-How exclusively relating to Compound A
and/or Compound B.

                                        2
<Page>

          1.11    "NDA" means an application (whether original, supplementary or
abbreviated) to the applicable Regulatory Authority in a country of the
Territory, for Regulatory Approval. An NDA, together with all supplemental
filings referencing the initial NDA filing, shall be deemed one and the same NDA
for all purposes of this Agreement.

          1.12    "NET SALES" means gross sales of Product by ALS, by any
Affiliates of ALS, or by any sublicensees of ALS, to unrelated third parties, in
arm's length transactions, including, but not limited to, pharmaceutical
wholesalers, managed healthcare organizations, pharmacies, hospitals or
dispensing physicians, less any of the following charges or expenses that are
incurred in connection with gross sales of the Product to such entities/persons
during the Term:

                  (a)   discounts, including cash discounts, customary trade
                        allowances or rebates actually taken, governmental
                        rebates, chargebacks, and group purchasing management
                        fees of up to three percent (3%) for formulary access;

                  (b)   credits or allowances given or made for rejection,
                        recall or return of previously sold Product actually
                        taken;

                  (c)   any tax or government charge, duty or assessment
                        (including any tax such as a value added or similar tax
                        or government charge) levied on the sale, transportation
                        or delivery of Product when included on the invoice or
                        other written document between the parties as payable by
                        the purchaser and collectable by ALS, its Affiliate or
                        sub-licensee; and

                  (d)   freight, postage, transportation, insurance and duties
                        on shipment of Product when included on the invoice or
                        other written document between the parties as payable by
                        the purchaser and collectable by ALS, its Affiliates or
                        sublicensees.

With respect to any gross sales of Product by ALS, by any Affiliates of ALS, or
by any sublicensees of ALS, to unrelated third parties in non-arm's length
transactions, "Net Sales" per unit of Product shall be determined by using the
"Net Sales" per unit of Product in arm's length transactions for the same
reporting period.

          1.13    "PATENTS" means the patent applications and patents listed in
EXHIBIT A hereto and any patents issuing upon such patent applications, any
amendments thereto, foreign equivalents in the Territory, and any and all
substitutions, extensions, additions, reissues, re-examinations, renewals,
divisions, continuations, continuations-in-part or supplementary protection
certificates derived from or relating thereto.

          1.14    "PHARMACEUTICAL USES" means any therapeutic use of Compound A,
Compound B and/or Product in any formulation or dosage form for the management
of a disease or condition of humans.

                                        3
<Page>

          1.15    "PRODRUG" means any compounds which, following administration,
are actively converted in the body to Compound A or Compound B.

          1.16    "PRODUCT" means any formulation containing either Compound A
or Compound B.

          1.17    "REGULATORY APPROVAL" means all governmental approvals and
authorizations necessary for the manufacture and commercial sale of a Product in
a country of the Territory, including, but not limited to, marketing
authorization, pricing approval and pricing reimbursement, as applicable.

          1.18    "REGULATORY AUTHORITY" means the United States Food and Drug
Administration ("FDA") or any successor entity and its equivalent in other
countries of the Territory, including, but not limited to, EMEA.

          1.19    "TERM" means the period commencing on the Effective Date and
ending as set forth in Section 9.1 below.

          1.20    "TERRITORY" means the entire world, except Japan.

          1.21    "VALID CLAIM" means a claim of an unexpired issued Patent that
has not been withdrawn, canceled or disclaimed nor held invalid or unenforceable
by a court or government agency of competent jurisdiction in an unappealed or
unappealable decision.

     2.   LICENSE GRANT. Subject to the terms and conditions of this Agreement,
Abbott hereby grants to ALS an Exclusive License in the Territory, under Abbott
Technology, for all Pharmaceutical Uses, with the right to grant sublicenses
pursuant to SECTION 5.5 hereof, to (i) research, develop, make or have made,
Compound A, Compound B and Product(s); (ii) apply for and obtain Regulatory
Approvals, all as may be required to manufacture and commercialize Product(s);
and (iii) register, use, import/export, market, offer to sell and sell,
Product(s) and Compound A and Compound B.

     3.   INFORMATION; EXCLUSIVITY.

          3.1     DELIVERY OF INFORMATION/CONSULTATION WITH ABBOTT PERSONNEL.

                  (a)   On or before December 31, 2004, Abbott shall, to the
                        extent it has not already done so, deliver to ALS the
                        information under Abbott's and its Affiliates' control
                        involving the Compounds constituting Patents and
                        Know-How excluding any attorney-client privileged
                        information. Abbott shall also, promptly after the
                        Effective Date, transfer to ALS Abbott's interests in
                        Investigational New Drug application no. 57,836, such
                        transfer being subject, in all respects, to applicable
                        Regulatory Approvals.

                  (b)   From the Effective Date until the six (6) month
                        anniversary of the Effective Date (the "CONSULTATION
                        PERIOD"), Abbott shall make its

                                        4
<Page>

                        technical personnel familiar with the development of
                        Compound A and/or Compound B available to ALS upon its
                        request for reasonable consultation at reasonable times
                        and places. ; provided, however, that Abbott shall not
                        be obligated to make any such personnel available at any
                        particular time if in doing so it would interfere with
                        Abbott's business operations (the "CONSULTATION
                        SERVICES"). During the Consultation Period, Abbott shall
                        provide a maximum of one hundred twenty (120) man hours
                        of Consultation Services (to the extent not utilized
                        under that certain Option Agreement between Abbott and
                        ALS dated as of October 29, 2004, as amended). The first
                        one hundred and twenty (120) man hours of such
                        Consultation Services shall be GRATIS to ALS and
                        thereafter, ALS shall pay Abbott $275.00 per hour (the
                        "CONSULTATION RATE") for such Consultation Services.
                        Abbott shall provide such Consultation Services on an
                        "as is" basis, without any representation or warranty as
                        to accuracy, completeness or quality. ALS shall have
                        sole responsibility for its decision to take or not take
                        any action based upon such Consultation Services, and
                        for the effect and consequences of such actions or
                        inactions. If, after the Consultation Period, ALS
                        requires any additional Consulting Services, ALS shall
                        make a request for such services in writing. Abbott
                        shall not be obligated to provide such additional
                        Consultation Services but it shall not unreasonably
                        withhold such Consultation Services from ALS. Any such
                        additional Consultation Services shall be billed at the
                        Consultation Rate. ALS agrees to reimburse Abbott for
                        all reasonable out-of-pocket expenses, if any, incurred
                        by Abbott in providing the Consultation Services. Abbott
                        shall invoice ALS for such expenses and ALS shall pay
                        such invoices with thirty (30) days of its receipt
                        thereof.

     4.   PURCHASE OF ABBOTT INVENTORY OF CLINICAL SUPPLIES, BULK COMPOUND AND
          CHEMICAL INTERMEDIATES.

          4.1     PURCHASE OF INVENTORY. ALS shall purchase approximately 1,125
kg. of bulk Compound A (the "Inventory").

          4.2     PURCHASE PRICE.

                  (a)   ALS shall pay to Abbott, as the purchase price for the
                        Inventory to be purchased under this ARTICLE 4, the
                        aggregate amount of Ten Million Dollars ($10,000,000),
                        payable as follows: (a) Two Million Dollars ($2,000,000)
                        upon the execution of this Agreement, (b) Seven Million
                        Dollars ($7,000,000) on or before May 1, 2005 and (c)
                        One Million Dollars ($1,000,000) on or before June 30,
                        2005. Abbott shall ship approximately a pro rata portion
                        of the Inventory to ALS upon receipt of each of the
                        foregoing payments (i.e. approximately twenty percent

                                        5
<Page>

                        (20%) of the Inventory shall be shipped by Abbott upon
                        receipt of the initial payment of Two Million Dollars
                        ($2,000,000)) unless otherwise agreed by the parties in
                        writing.

          4.3     TESTING OF INVENTORY. At any time after the Effective Date,
ALS shall have the right to have its personnel present to witness the removal
and testing of samples of the Inventory. Abbott shall make reasonable efforts to
provide ALS with advance notice of such testing and sampling. ALS shall have the
right to review and take copies of the test records relating to such sampling
and testing. Abbott shall use reasonable commercial efforts to complete the
tests described in the Schedule of Release Specification Tests set forth in
EXHIBIT B no later than the December 6, 2004. If, using the tests described in
the Schedule of Release Specification Tests, it is determined that GREATER THAN
OR EQUAL TO ninety percent (90%) of the Inventory meets the release
specifications set forth in the Schedule of Release Specification Tests set
forth in Exhibit B, ALS shall be deemed to have accepted the Inventory. If, in
the alternative, it is determined that LESS THAN ninety percent (90%) of the
Inventory meets the release specifications set forth in the Schedule of Release
Specification Tests set forth in Exhibit B, ALS shall be deemed to have accepted
the Inventory; provided, however, that ALS and Abbott shall thereafter negotiate
in good faith a reduction in the purchase price for the Inventory that is
commensurate with such shortfall in Inventory. ALS shall have the right to
submit the results of the Release Specification Tests set forth in Exhibit B to
a Regulatory Authority.

     5.   DEVELOPMENT/MANUFACTURING/MARKETING/DISTRIBUTION BY ABBOTT/OTHER.

          5.1     CLINICAL DEVELOPMENT. ALS shall use commercially reasonable
and diligent efforts to develop the Compounds for one or more treatment
indications. For purposes of this SECTION 5.1(a), development of an indication
shall be deemed to have commenced upon enrollment of the first subject in the
first clinical study for an indication using the formulation selected for
clinical development. ALS shall have sole responsibility for designing,
conducting and paying for the cost of the clinical development of Product and
shall use commercially reasonable efforts to diligently conduct such clinical
development.

          5.2     COMMERCIALIZATION. ALS shall, assuming Regulatory Approval,
use commercially reasonable efforts to commercialize Product in the United
States and the European Union by itself or through its Affiliates and
sublicensees, using at least that level of effort as a pharmaceutical company of
comparable size and resources would use with similar compounds.

                                        6
<Page>

          5.3     MARKETING. ALS shall have sole responsibility for marketing
Product, including entering into any co-marketing and/or co-promotion
arrangements. ALS shall distribute all Product samples in the United States in
accordance with the Prescription Drug Marketing Act.

          5.4     MANUFACTURING. ALS and its Affiliates shall have sole
responsibility for manufacturing Product.

          5.5     SUBLICENSING. ALS may sublicense its rights under this
Agreement at any time without obtaining Abbott's consent.

          5.6     DISTRIBUTION BY ABBOTT. If ALS determines that Product should
be marketed or distributed by ALS and a co-marketer or a co-distributor in any
country or countries of the Territory, it shall grant Abbott a "Right of First
Negotiation" (as hereinafter defined) to become the co-marketer or
co-distributor with ALS, in such countries. If ALS determines that Product
should be marketed by a sole distributor in any country or countries of the
Territory, it shall grant Abbott the "Right of First Negotiation" to become the
exclusive distributor in such countries. "RIGHT OF FIRST NEGOTIATION" shall mean
the exclusive right, for a period of ninety (90) days, to negotiate with ALS to
agree upon and execute a definitive agreement to become the co-marketer,
co-distributor or exclusive distributor, as the case may be. ALS and Abbott
shall negotiate in good faith with each other during such period. Such period
shall commence on the receipt of notice by Abbott from ALS that ALS has
determined how a Product will be marketed in any one or more specified countries
and specifying whether such marketing shall be done by co-marketing,
co-distribution, or exclusive distribution. If such ninety (90) day period
expires and a definitive agreement has not been executed with respect to the
country or countries specified in such notice, ALS shall thereafter have no
obligation to Abbott with respect to co-marketing, co-distribution or exclusive
distribution in such country or countries.

     6.   FINANCIALS.

          6.1     MILESTONES. ALS shall make the following milestone payments to
Abbott within twenty (20) business days of the following events:

                                        7
<Page>

<Table>
<Caption>
MILESTONE                                                     PAYMENT
--------------------------------------------------------    ------------
<S>                                                         <C>
The  earlier  to  occur  of  October  31,  2005 or the      $  5,000,000
commencement of clinical trials (administration to first
patient) of Compound A or Compound B by ALS

Submission of an NDA for Compound A or Compound B for       $ 10,000,000
the United States. In the event that ALS submits an NDA
for Compound A or Compound B to the European Union prior
to submission in the United States, ALS shall pay to
Abbott one half (1/2) of the milestone due under this
term upon submission to the European Union and the
balance of this milestone shall become due upon
submission of an NDA for Compound A or Compound B in the
United States.

Receipt of Regulatory Approval of Compound A or Compound    $ 30,000,000
B in the United States. In the event that ALS receives
Regulatory Approval of Compound A or Compound B in the
European Union prior to receipt of Regulatory Approval
in the United States, ALS shall pay to Abbott one half
(1/2) of the milestone due under this term upon
Regulatory Approval in the European Union and the
balance of this milestone shall become due upon receipt
of Regulatory Approval of Compound A or Compound B in
the United States.
</Table>

          6.2     ROYALTY PAYMENTS.

                  (a)   RUNNING ROYALTY. Beginning with the First Commercial
                        Sale by ALS, any Affiliates or sublicensees of ALS, ALS
                        shall pay to Abbott, on a country-by-country basis, a
                        royalty of (i) nineteen percent (19%) on Net Sales, with
                        respect to which, but for the license granted hereunder,
                        the manufacture, use or sale of Product would infringe a
                        Valid Claim in such country. and (ii) nine and one-half
                        percent (9.5%) on Net Sales for all other countries;
                        provided, however, that ALS shall not be obligated to
                        pay any royalties for countries in which all Valid
                        Claims have expired; and provided further, however, that
                        (A) ALS shall only be obligated to make payments under
                        this Section 6.2(a)(ii), on a country-by-country basis
                        for a period of seven (7) years from the date of the
                        First Commercial Sale in each such country and (B) ALS
                        shall not be obligated to pay the nine and one-half
                        percent (9.5%) royalty established in Section 6.2
                        (a)(ii) in a given country in the event that all
                        Covering Claims are deemed invalid by the judicial
                        authority in such country effective as of the date that
                        the last Covering Claim is finally deemed invalid. For
                        purposes of this Section 6.2(a), the term "Covering
                        Claim" shall mean a claim contained in any of the
                        Patents that would be infringed but for the Exclusive
                        License granted hereunder.

                                        8
<Page>

                  (b)   ROYALTY REPORTS AND PAYMENTS. Beginning with the First
                        Commercial Sale anywhere in the Territory, within
                        forty-five (45) days after the end of each calendar
                        quarter, ALS shall prepare and deliver to Abbott a
                        report detailing the calculation of Net Sales in the
                        Territory, on a country-by-country basis, for such just
                        ended quarter along with the calculation of royalties
                        due thereon pursuant to SECTION 6.2(a) above. Each
                        report shall be accompanied by full payment in U.S.
                        dollars of the royalties shown thereon to be due. In the
                        event that conversion from foreign currency is required
                        in calculating a royalty payment hereunder, the exchange
                        rate used shall be the average of the bid and ask rates
                        in effect at the end of the last business day of the
                        applicable quarter for which royalties are calculated,
                        as reported by THE WALL STREET JOURNAL (Midwest
                        Edition), or a substantially similar global publication
                        if THE WALL STREET JOURNAL (Midwest Edition) is no
                        longer published.

                  (c)   BOOKS AND RECORDS/AUDIT RIGHTS. ALS shall keep, and
                        shall cause its Affiliates and sublicensees to keep,
                        books and records accurately showing all Products
                        manufactured, used or sold under the terms of this
                        Agreement. The relevant portions of such books and
                        records shall be open to inspection by representatives
                        of (i) Abbott and (ii) either or both of the two (2)
                        third parties that Abbott certifies that had as of the
                        Effective Date of the Option Agreement between Abbott
                        and ALS a legitimate financial interest in either of the
                        Compounds, at Abbott's cost, solely for the purposes of
                        determining the correctness of the royalties payable
                        under this Agreement. Such audit, conducted no more than
                        one time per calendar year, shall be during normal
                        business hours after reasonable advance notice and
                        subject to customary confidentiality provisions. In the
                        event an audit shows a deficiency to be due, ALS shall
                        immediately pay such deficiency along with the
                        reasonable costs and expenses of the audit if the
                        deficiency is more than five percent (5%) of the amount
                        due during such audited period. If the audit shows that
                        an excess was paid, ALS may deduct the amount of such
                        excess from the next payment due. Such books and records
                        shall be preserved for a period of at least three (3)
                        years after the date of the royalty payment to which
                        they pertain, and no audit may be conducted with respect
                        to royalties due in any calendar year that is more than
                        two (2) years preceding the calendar year in which the
                        audit is being conducted. Books and records for a given
                        calendar year may only be audited once. Any third party
                        exercising its audit rights under this Section 6.2 shall
                        enter into a confidentiality agreement with terms no
                        less stringent than those contained in this Agreement.

                  (d)   WITHHOLDING TAXES ON ROYALTIES. Where any sum due to be
                        paid to Abbott hereunder is subject to any withholding
                        or similar tax,

                                        9
<Page>

                        the parties shall use reasonable efforts to do such acts
                        and things and to sign such documents as will enable
                        them to take advantage of any applicable double taxation
                        agreement or treaty. In the event there is no applicable
                        double taxation agreement or treaty, or if an applicable
                        double taxation agreement or treaty reduces but does not
                        eliminate such withholding or similar tax, ALS shall pay
                        such withholding or similar tax to the appropriate
                        government authority, deduct the amount paid from the
                        amount due Abbott and secure and send to Abbott the best
                        available evidence of such payment sufficient to enable
                        Abbott to obtain a deduction for such withheld taxes or
                        obtain a refund thereof.

     7.   REPRESENTATIONS, WARRANTIES AND COVENANTS.

          7.1     REPRESENTATIONS AND WARRANTIES OF ABBOTT. Abbott represents
and warrants that:

                  (a)   it is duly organized, validly existing and in good
                        standing under the laws of Illinois, that it has full
                        corporate power and authority to enter into this
                        Agreement and to carry out its provisions, and that
                        there are no outstanding agreements, assignments or
                        encumbrances in existence to which Abbott is a party or
                        otherwise bound that are inconsistent with the
                        provisions of this Agreement.

                  (b)   the Patents have not been, and will not be, knowingly
                        obtained by Abbott through any activity, omission or
                        representation that would limit or destroy the validity
                        of the Patents or cause the Patents to be deemed
                        unenforceable;

                  (c)   there are no actions pending or, to the knowledge of
                        Abbott, threatened against Abbott before any court,
                        relating to the Abbott Technology;

                  (d)   Abbott has no knowledge of the Abbott Technology being
                        infringed by others; and the Abbott Technology comprises
                        all of the patents and patent applications owned by or
                        licensed to Abbott or its Affiliates that claim either
                        Compound A or Compound B, their use or manufacture;

                  (e)   all of the Inventory to be purchased in accordance with
                        ARTICLE 4 hereof (i) was manufactured in accordance with
                        Abbott's internal specifications, (ii) when delivered
                        hereunder to ALS will meet Abbott's release
                        specifications for use in human clinical trials, and
                        (iii) was manufactured in accordance with FDA Current
                        Good Manufacturing Practices as defined in 21 C.F.R.
                        Part 210;

                                       10
<Page>

                  (f)   it has authorized the execution and delivery this
                        Agreement and the performance of its obligations
                        hereunder and that the execution, delivery and
                        performance of this Agreement by it does not require the
                        consent, approval or authorization of or notice to, or
                        filing or registration with, any governmental agency or
                        Regulatory Authority;

                  (g)   except for the Compounds, it currently has not entered
                        in any stage of human clinical trials, any compound that
                        would fall in the ketolide antibiotic class as such term
                        is commonly used;

                  (h)   it is the sole owner or exclusive licensee of all patent
                        applications and patents within the Patents, provided
                        that no representation is made under this Section 7.1(h)
                        (i) regarding the content, scope, validity or
                        enforceability of such applications or patents or any
                        intellectual property rights relating thereto or (ii)
                        that engagement in the activities described in such
                        applications or patents does not or would not infringe
                        the rights of any third party;

                  (i)   none of its patent counsel, commercial counsel or
                        executive officers with responsibility for
                        pharmaceutical matters have knowledge (without having
                        conducted any investigation or inquiry) of any third
                        party rights necessary to develop, make, use or sell
                        Compound A or Compound B in the Territory; and

                  (j)   it has not received written notice from any third party
                        that the manufacture or sale of the Compounds infringes
                        the rights of any third party.

          7.2     REPRESENTATIONS AND WARRANTIES OF ALS. ALS represents and
warrants that:

                  (a)   it is duly organized, validly existing and in good
                        standing under the laws of Delaware, that it has full
                        corporate power and authority to enter into this
                        Agreement and to carry out its provisions, and that
                        there are no outstanding agreements, assignments or
                        encumbrances in existence to which ALS is a party or
                        otherwise bound that are inconsistent with the
                        provisions of this Agreement;

                  (b)   it has authorized the execution and delivery of this
                        Agreement and the performance of its obligations
                        hereunder; and

                  (c)   the execution, delivery and performance of this
                        Agreement by it does not require the consent, approval
                        or authorization of or notice to, or filing or
                        registration with, any governmental agency or Regulatory
                        Authority.

                                       11
<Page>

          7.3     INDEMNIFICATION BY ALS. ALS shall indemnify and hold Abbott,
its Affiliates and their respective directors, officers, employees and agents
harmless from and against any and all liabilities, actions, suits, claims,
demands, prosecutions, damages, costs, expenses or money judgments finally
awarded (including reasonable legal fees and costs of investigation and
litigation) (collectively, "LIABILITIES") incurred by or instituted or rendered
against or suffered by Abbott to the extent such Liabilities result from a third
party claim arising from the sale, distribution, transportation, handling or use
of Compound A or Compound B or Product(s) in the Territory by ALS, its
Affiliates, agents or sublicensees or any health care professional, patient or
other third party, or from the willful misconduct or the negligent acts or
omissions of ALS, its Affiliates, their agents or sublicensees or ALS's breach
of this Agreement, except to the extent such third party claims arise out of the
negligence or willful misconduct of Abbott, or any of its Affiliates or any of
their respective directors, officers, employees and agents. Abbott shall give
ALS prompt notice in writing of any such claim or lawsuit and permit ALS to
undertake sole control of the defense and settlement thereof at ALS's expense.
In any such claim or lawsuit:

                  (a)   Abbott will cooperate in the defense by providing access
                        to witnesses and evidence available to it. Abbott shall
                        have the right to participate, at its expense, in any
                        defense to the extent that in its judgment Abbott may be
                        prejudiced by ALS's sole defense thereof.

                  (b)   Any settlement for which Abbott intends to seek or has
                        sought indemnification hereunder from ALS shall not be
                        binding upon ALS without the written consent of ALS.

          7.4     INDEMNIFICATION BY ABBOTT. Abbott shall indemnify and hold
ALS, its Affiliates and their respective directors, officers, employees and
agents harmless from and against any and all Liabilities incurred by or
instituted or rendered against or suffered by ALS to the extent such Liabilities
result from a third party claim arising from the willful misconduct or the
negligent acts or omissions of Abbott, its Affiliates, their agents or
sublicensees, or Abbott's breach of this Agreement, except to the extent such
third party claims arise out of the negligence or willful misconduct of ALS, or
any of its Affiliates or any of their respective directors, officers, employees
and agents. ALS shall give Abbott prompt notice in writing of any such claim or
lawsuit and permit Abbott to undertake sole control of the defense and
settlement thereof at Abbott's expense. In any such claim or lawsuit:

                  (a)   ALS will cooperate in the defense by providing access to
                        witnesses and evidence available to it. ALS shall have
                        the right to participate, at its expense, in any defense
                        to the extent that in its judgment ALS may be prejudiced
                        by Abbott's sole defense thereof.

                  (b)   Any settlement for which ALS intends to seek or has
                        sought indemnification hereunder from Abbott shall not
                        be binding upon Abbott without the written consent of
                        Abbott.

                                       12
<Page>

          7.5     REPORTABLE ADVERSE EVENTS. Each party warrants that it shall
advise the other of any serious adverse events relating in any way to the
Compounds or the Product as and when such serious adverse events are reported or
reportable by it to the Regulatory Authorities.

          7.6     COMPLIANCE WITH LAW. In its activities relating to this
Agreement, each party covenants to the other party that it shall comply with all
applicable laws, rules and regulations.

          7.8     LIMITATION. EXCEPT FOR THE EXPRESS WARRANTIES IN THIS
ARTICLE 7, NEITHER PARTY MAKES ANY WARRANTIES, EXPRESS OR IMPLIED, IN FACT OR BY
OPERATION OF LAW, STATUTORY OR OTHERWISE. EACH PARTY SPECIFICALLY DISCLAIMS ANY
IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. EXCEPT
FOR AMOUNTS FINALLY AWARDED FOR INDEMNIFICATION FOR THIRD PARTY LIABILITIES
UNDER SECTIONS 7.3 AND 7.4 ABOVE, NEITHER PARTY SHALL BE LIABLE TO THE OTHER
PARTY HERETO OR TO ANY THIRD PARTY FOR ANY SPECIAL, CONSEQUENTIAL, EXEMPLARY OR
INCIDENTAL DAMAGES (INCLUDING LOST OR ANTICIPATED PROFITS RELATING TO THE SAME)
ARISING FROM ANY CLAIM RELATING TO THIS AGREEMENT, WHETHER SUCH CLAIM IS BASED
ON CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, EVEN IF AN AUTHORIZED
REPRESENTATIVE OF SUCH PARTY IS ADVISED OF THE POSSIBILITY OR LIKELIHOOD OF
SAME.

     8.   CONFIDENTIALITY AND NON-DISCLOSURE.

          8.1     NONDISCLOSURE. Neither party shall use or disclose any
Confidential Information received by it from the other party pursuant to this
Agreement without the prior written consent of the other. This obligation will
continue for a period of seven (7) years after termination of this Agreement or
expiration of the Term.

          8.2     RESTRICTION. Each party shall restrict dissemination of
Confidential Information of the other party to those of its employees,
Affiliates, contractors, agents and sublicensees (if any) who have a need
therefore in carrying out their functions. Neither party shall obtain any right
of any kind to the Confidential Information of the other party by virtue of this
Agreement, except as granted under this Agreement.

          8.3     RESTRICTION EXEMPTIONS. Nothing contained in this ARTICLE 8 or
SECTION 1.4 shall be construed to restrict the parties from using or disclosing
Confidential Information solely to the extent and solely as required:

                  (a)   for regulatory, tax or customs reasons;

                  (b)   for audit purposes;

                  (c)   by court order or other governmental order or request;

                                       13
<Page>

                  (d)   to perform acts permitted by this Agreement, including
                        (i) disclosure by ALS to third parties undertaking
                        clinical trials and the like on behalf of ALS, so long
                        as such third parties are under a legal obligation to
                        ALS to protect the confidentiality of such Confidential
                        Information, (ii) disclosure by ALS to sublicensees, so
                        long as such sublicensees are under a legal obligation
                        to ALS to protect the confidentiality of such
                        Confidential Information or (iii) disclosure by ALS or
                        its sublicensees in connection with the marketing and
                        commercial sale of Product, to the extent required by
                        law; or

                  (e)   as required by ALS in connection with a private or
                        public financing.

     9.   TERM AND TERMINATION.

          9.1     The Term of this Agreement shall continue in effect until the
last to expire of the Patents unless earlier terminated as provided in this
ARTICLE 9. Upon the expiration of the Term, ALS shall have a non-exclusive,
perpetual and irrevocable license under Abbott's Know-How, without any further
payment obligation to Abbott, except for the payment obligations accruing prior
to such date and the indemnification obligations under SECTION 7.3.

          9.2     ALS shall have the right, without cause, to terminate this
Agreement upon sixty (60) days' written notice, at the end of which the
termination shall be effective. Before such termination becomes effective, ALS
shall pay all payments and royalties which may have become due prior to the
effective date of such termination. Upon such termination, ALS shall assign and
deliver without charge, and Abbott shall be entitled to retain for its own use,
all materials (Compounds, bulk and processed clinical material), studies and
information relating to the Compounds.

          9.3     Either party may terminate this Agreement by giving to the
other party prior written notice of not less than thirty (30) days in the case
of a monetary breach and of not less than ninety (90) days in the event the
other party shall commit a non-monetary material breach of this Agreement, and
such breaching party shall fail to cure such breach during such thirty (30) or
ninety (90) day period, as applicable. No such cancellation and termination
shall release the breaching party from any obligations hereunder incurred prior
thereto. If, in any dispute submitted for resolution pursuant to Section 13.8,
the neutral determines that there has been a material breach of the Agreement,
the breaching party shall not be entitled to an additional cure period, but
rather, the non-breaching party may immediately terminate this Agreement.

          9.4     Either party may terminate this Agreement on thirty (30) days
notice if the other party passes a resolution or a court of competent
jurisdiction makes an order for its winding up; or ceases its business
operations.

                                       14
<Page>

          9.5     Abbott may terminate this Agreement immediately if ALS,
directly or indirectly, commences or participates in any proceedings in order to
have any of the Patents declared invalid in any country.

          9.6     Termination of this Agreement shall be without prejudice to
any rights of either party against the other which may have accrued up to the
date such termination becomes effective.

          9.7     All causes of action accruing to either party under this
Agreement shall survive expiration or termination of this Agreement for any
reason.

          9.8     Upon any termination or expiration of this Agreement, each
party shall promptly return to the other party all written Confidential
Information of such other party, and all copies thereof (retaining one copy of
the Confidential Information of the other in its confidential files for archival
purposes only), which is not covered by a paid-up license or other rights
specified herein surviving such termination or expiration. Further, upon
termination of this Agreement in whole or in part, except upon termination of
this Agreement by ALS pursuant to Sections 9.3 or 9.4 above, ALS shall act
promptly to ensure a smooth transition of rights to Abbott, including but not
limited to the transfer of any and all relevant Regulatory Approvals to Abbott.

     10.  INFRINGEMENT OF PATENTS BY THIRD PARTY. In the event of an actual or
suspected infringement of a Patent by a third party, the following shall apply:

          10.1    NOTICE. Each party shall give the other written notice if one
of them becomes aware of any infringement by a third party of any Patent. Upon
notice of any such infringement, the parties shall promptly consult with one
another with a view toward reaching agreement on a course of action to be
pursued.

          10.2    ALS'S RIGHT TO BRING INFRINGEMENT ACTION.

                  (a)   ALS ELECTION. If a third party infringes any Patent,
                        Abbott shall have the first right, but not the
                        obligation, to institute and prosecute an action or
                        proceeding to abate such infringement and to resolve
                        such matter by settlement or otherwise.

                        (i)    Abbott shall notify ALS of its intention to bring
                               an action or proceeding prior to filing the same
                               and in sufficient time to allow ALS the
                               opportunity to discuss with Abbott the choice of
                               counsel for such matter. Abbott shall keep ALS
                               timely informed of material developments in the
                               prosecution or settlement of such action or
                               proceeding. Abbott shall be responsible for all
                               fees and expenses of any action or proceeding
                               against infringers which Abbott initiates. ALS
                               shall cooperate fully at its expense by joining
                               as a party plaintiff if reasonably requested to
                               do so

                                       15
<Page>

                               by Abbott or if required to do so by law to
                               maintain such action or proceeding and by
                               executing and making available such documents
                               as Abbott may reasonably request. ALS may be
                               represented by counsel in any such legal
                               proceedings, at ALS's own expense.

                        (ii)   If Abbott elects not to exercise such first right
                               it shall notify ALS of its determination in
                               writing. Thereafter, ALS shall have the right, at
                               its discretion, to institute and prosecute an
                               action or proceeding to abate such infringement
                               and to resolve such matter by settlement or
                               otherwise. ALS shall keep Abbott timely informed
                               of material developments in the prosecution or
                               settlement of such action or proceeding. ALS
                               shall be responsible for all fees and expenses of
                               any action or proceeding against infringers which
                               ALS initiates. Abbott shall cooperate fully by
                               joining as a party plaintiff if reasonably
                               requested to do so by ALS or if required to do so
                               by law to maintain such action and by executing
                               and making available such documents as ALS may
                               reasonably request. Abbott may be represented by
                               counsel in any such action, at its own expense.

                  (b)   ALS'S USE OF PROCEEDS. All amounts of every kind and
                        nature recovered from an action or proceeding of
                        infringement brought by ALS shall belong to ALS, and
                        shall be used first to reimburse ALS for its documented
                        and actual costs of prosecution, including attorneys'
                        fees, expert fees and all other related expenses, second
                        to reimburse Abbott for its documented and actual costs
                        if it is represented by counsel in the proceedings, and
                        the balance shall thereafter be treated as Net Sales.

                  (c)   ABBOTT'S USE OF PROCEEDS. All amounts of every kind and
                        nature recovered from an action or proceeding of
                        infringement brought by Abbott shall belong to Abbott,
                        and shall first be used to reimburse Abbott for its
                        documented and actual costs of prosecution, including
                        attorneys' fees, expert fees and all other related
                        expenses, second to reimburse ALS for its documented and
                        actual costs if it is represented by counsel in the
                        proceedings, and the balance shall thereafter belong to
                        Abbott.

     11.  INFRINGEMENT OF THIRD PARTY RIGHTS; ALS DEFENSE OF SUIT. If Abbott,
its Affiliates, ALS, its Affiliates, sublicensees, distributors or other
customers are sued or threatened with suit by a third party alleging
infringement in one or more countries of the Territory of such party's patents
or other intellectual property rights that are alleged to cover the manufacture,
use, sale, import. export or distribution of one or more Products, Abbott or
ALS, whichever is applicable, will promptly notify the other in writing and
provide a copy of the lawsuit or claim. The party being sued or threatened with
suit shall control the defense in any such claim or suit.

                                       16
<Page>

Such party shall have the right to settle any such suit, including the right to
grant one or more sublicenses with the other party's prior written approval,
which approval shall not unreasonably be withheld, provided that ALS shall not
otherwise have the right to surrender, limit or adversely affect any rights to
the Patents. ABBOTT MAKES NO WARRANTIES AND SPECIFICALLY DISCLAIMS ANY
WARRANTIES REGARDING THE NON-INFRINGEMENT BY THE PRODUCTS OF THIRD PARTY RIGHTS.

     12.  PATENT PROSECUTION AND MAINTENANCE; PATENT COSTS; PATENT TERM
          EXTENSION.

          12.1    DISCLOSURE OF PATENTS/APPLICATIONS TO ALS. Within thirty (30)
days following the Effective Date, Abbott shall, to the extent not previously
disclosed, disclose to ALS the complete text of, and all other information in
its possession or control directly related to (a) all patent applications
included in the Patents filed anywhere in the Territory; and (b) all patents
included in the Patents as well as all information in Abbott's, its Affiliates
and its patent counsel's possession concerning the institution or possible
institution of any interference, opposition, reexamination, reissue, revocation,
nullification or any official proceeding involving an issued patent included in
the Patents anywhere in the Territory. ABBOTT MAKES NO WARRANTIES AND
SPECIFICALLY DISCLAIMS ANY WARRANTIES REGARDING THE PATENTABILITY OF PENDING
PATENT APPLICATIONS.

          12.2    PROSECUTION AND MAINTENANCE. Abbott shall file, prosecute and
maintain all of the Patents in Abbott's name, including oppositions and
interferences. In the event that Abbott determines to abandon any patent
application that is included in the Patents or to no longer maintain any patent
that is included within the Patents, Abbott shall give ALS ninety (90) days
prior written notice before taking any action or inaction in furtherance of such
determination during which time ALS shall have the right but not the obligation
to assume the prosection of such patent application or the maintenance of such
patent. Abbott and ALS shall consult and cooperate with each other, and Abbott
shall keep ALS reasonably informed, with respect to the prosecution and
maintenance of the Patents hereunder. Abbott will provide ALS with copies of all
material correspondence sent to or received from the United States Patent and
Trademark Office in connection with the prosecution and maintenance of the
Patents. Abbott shall provide copies in a timely manner to allow ALS an
opportunity, if it so elects, to review and comment on Abbott's proposed patent
strategy.

                                       17
<Page>

     13.  MISCELLANEOUS.

          13.1    FORCE MAJEURE. If the performance by either party of any of
its obligations under this Agreement (except the obligation to pay money) shall
be prevented by circumstances beyond its reasonable control which could not have
been avoided by the exercise of reasonable diligence, then such party shall be
excused from the performance of that obligation for the duration of the event.
The affected party shall promptly notify the other party in writing should such
circumstances arise, give an indication of the likely extent and duration
thereof, and shall use commercially reasonable efforts to resume performance of
its obligations as soon as practicable.

          13.2    NOTICES. Any notice required to be given or made under this
Agreement by one of the parties hereto to the other shall be in writing, by
personal delivery, registered U.S. mail or overnight courier, addressed to such
other party at its address indicated below, or to such other address as the
addressee shall have last furnished in writing to the addressor and shall be
effective upon the date of receipt.

If to ALS:                Advanced Life Sciences Holdings, Inc.
                          1440 Davey Road
                          Woodridge, Illinois 60517
                          Attn:  Michael T. Flavin, Ph.D.,
                                 Chairman and Chief Executive Officer

With copy to:             Winston & Strawn, LLP
                          35 West Wacker Drive
                          Chicago, IL 60601
                          Attn:  Thomas P. Fitzgerald

If to Abbott:             Abbott Laboratories
                          100 Abbott Park Road
                          Department 309; Building AP30
                          Abbott Park, Illinois 60064-3537

With a copy to:           Abbott Laboratories
                          100 Abbott Park Road
                          Department 322; Building AP6D
                          Abbott Park, Illinois 60064-6049
                          Attn:  Divisional Vice President, Domestic Legal

          13.3    APPLICABLE LAW/COMPLIANCE. This Agreement shall be governed by
and construed in accordance with the laws of the State of Illinois, excluding
its conflict of laws provision. Each party hereto shall comply with all
applicable laws, rules, ordinances, guidelines, consent decrees and regulations
of any federal, state or other governmental authority.

          13.4    ENTIRE AGREEMENT. This Agreement and the attachments
(Exhibits) contain the entire understanding of the parties with respect to the
subject matter hereof. All express or implied agreements and understandings,
either oral or written, heretofore made are

                                       18
<Page>

expressly merged in and made a part of this Agreement. This Agreement may be
amended, or any term hereof modified, only by a written instrument duly executed
by both parties hereto.

          13.5    COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

          13.6    SEVERABILITY/HEADINGS. If any provision of this Agreement is
deemed unenforceable, the remainder of the Agreement will not be affected and,
if appropriate, the parties will attempt to replace the unenforceable provision
with a new provision that, to the extent possible, reflects the parties'
original intent. The captions and headings used in this Agreement are for
reference only and are not to be construed in any way as terms or used to
interpret the provisions of this Agreement.

          13.7    ASSIGNMENT. Neither party may, without prior written consent
of the other, assign this Agreement or transfer its interest or any part thereof
under this Agreement to any third party except that either party may assign this
Agreement without such consent (i) to the surviving entity in a merger or
consolidation involving such party; (ii) to a third party that acquires all or
substantially all of the assets or the business of such party to which this
Agreement pertains; or (iii) to any Affiliate of that party and such party
hereby guarantees the performance by such Affiliate. A sale of shares of stock
shall not constitute an assignment in violation of this section. For purposes of
this Article 14, the term "Affiliate" means any corporation, company,
partnership, joint venture and/or other entity which controls, is controlled by,
or is under common control of either party hereto. For purposes of this
definition, control shall mean direct or indirect ownership of more than fifty
percent (50%) of the stock or participating shares entitled to vote for the
election of directors (but only as long as such ownership exists).

          13.8    DISPUTE RESOLUTION. The parties hereto shall attempt to settle
any dispute arising out of or relating to this Agreement in an amicable way.
Except for claims for injunctive or other equitable relief, which may be brought
in any court of competent jurisdiction, any controversy, claim or right of
termination for cause which may arise under, out of, in connection with, or
relating to this Agreement, or any breach thereof, shall be settled according to
the Alternative Dispute Resolution provisions attached hereto as EXHIBIT C.

          13.9    INDEPENDENT CONTRACTOR. It is understood that both parties
hereto are independent contractors and engage in the operation of their own
respective businesses and neither party hereto is to be considered the agent of
the other party for any purpose whatsoever and neither party has any authority
to enter into any contract or assume any obligation for the other party or to
make any warranty or representation on behalf of the other party. Each party
shall be fully responsible for its own employees, servants and agents, and the
employees, servants and agents of one party shall not be deemed to be employees,
servants and agents of the other party for any purpose whatsoever.

          13.10   PUBLICITY. No press release or other public announcement shall
be made by either party concerning the execution of this Agreement or the fact
that ALS has licensed the Compounds from Abbott, without the prior written
consent of the non--disclosing party, which

                                       19
<Page>

consent may be withheld in the non-disclosing party's sole discretion. Neither
party shall use the name of the other party, its officers, employees or agents
without the other party's prior written consent, except where the name of the
other party must be disclosed as a matter of law. ALS anticipates that it will
make an initial public offering of its securities during the Option Term and
that disclosure of a summary of the terms of this Agreement may be required to
be included in a registration statement to be filed with the Securities and
Exchange Commission pertaining to such initial public offering. If, in good
faith, counsel for ALS determines that such disclosure is required, ALS shall
give Abbott written notice thereof not less than thirty (30) days prior to the
making of any such filing, together with a draft of the disclosure ALS intends
to make regarding this Agreement. Abbott shall have fifteen (15) days to review
and comment on the draft of the disclosure. ALS shall use all reasonable efforts
to incorporate Abbott's comments. Should either party wish to make a disclosure
or be required by law to make a disclosure under circumstances other than those
described above, the disclosing party shall submit a copy of the proposed
disclosure to the other party for review. The non--disclosing party shall have
three (3) weeks to review and comment on the content of such disclosure. In the
case of a disclosure required by law, the disclosing party, subject to legal
requirements, shall use all reasonable efforts to accommodate the
non--disclosing party's comments. For non--routine matters like an emergency,
special circumstance, or other situation where the law compels a disclosure in
less than three (3) week's time, the non-disclosing party agrees to use
commercially reasonable efforts to provide its review and comment in order to
meet the disclosing party's timetable.

                            [SIGNATURE PAGE FOLLOWS]

                                       20
<Page>

                     [SIGNATURE PAGE TO LICENSE AGREEMENT ]

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the Effective Date.

ABBOTT LABORATORIES                                  ADVANCED LIFE SCIENCES
                                                     HOLDINGS, INC.

<Table>
<S>                                                  <C>
By:   /s/ Jeffrey M. Leiden, Ph.D.                   By:   /s/ Michael T. Flavin, Ph.D.
      ------------------------------------                 ------------------------------------
Name: Jeffrey M. Leiden, M.D., Ph.D.                       Name: Michael T. Flavin, Ph.D.
Its:  President and Chief Operating Officer,         Its:  Chairman and Chief Executive
      Pharmaceutical Products Group                        Officer
</Table>

                                       21
<Page>

                                    EXHIBIT A

                         PATENTS AND PATENT APPLICATIONS

                                 (SEE ATTACHED.)

                                       A-1
<Page>

                                    EXHIBIT B

                     SCHEDULE OF RELEASE SPECIFICATION TESTS

<Table>
<S>                                           <C>
1.  Assay by HPLC                             Not less than 950 mcg/mg on the anhydrous basis

2.  Impurities/Related Substances (by HPLC)   Report results for 2-epimer (RRT About 0.91)
                                              Not more than 2.00% of cis-A195773 (RRT about 1.10)
                                              Not more than 5.00% total impurities
                                              No other single unknown impurity greater that 1.00%
                                              No other single known impurity greater than 1.50%

3.  Moisture (Karl Fischer)                   Not more than 2.0%

4.  X-Ray Diffraction                         Report pattern observed

5.  Physical Examination                      Appearance: Powder; some soft lumps may be present
                                              Color: White to light tan
</Table>

                                       B-1
<Page>

                                    EXHIBIT C

                         ALTERNATIVE DISPUTE RESOLUTION

The parties recognize that from time to time a dispute may arise relating to
either party's rights or obligations under this Agreement. The parties agree
that any such dispute shall be resolved by the Alternative Dispute Resolution
("ADR") provisions set forth in this Exhibit, the result of which shall be
binding upon the parties.

To begin the ADR process, a party first must send written notice of the dispute
to the other party for attempted resolution by good faith negotiations between
their respective presidents (or their designees) of the affected subsidiaries,
divisions, or business units within twenty-eight (28) days after such notice is
received (all references to "days" in this ADR provision are to calendar days).
If the matter has not been resolved within twenty-eight (28) days of the notice
of dispute, or if the parties fail to meet within such twenty-eight (28) days,
either party may initiate an ADR proceeding as provided herein. The parties
shall have the right to be represented by counsel in such a proceeding.

     1. To begin an ADR proceeding, a party shall provide written notice to the
     other party of the issues to be resolved by ADR. Within fourteen (14) days
     after its receipt of such notice, the other party may, by written notice to
     the party initiating the ADR, add additional issues to be resolved within
     the same ADR.

     2. Within twenty-one (21) days following receipt of the original ADR
     notice, the parties shall select a mutually acceptable neutral to preside
     in the resolution of any disputes in this ADR proceeding. If the parties
     are unable to agree on a mutually acceptable neutral within such period,
     either party may request the President of the CPR Institute for Dispute
     Resolution ("CPR"), 366 Madison Avenue, 14th Floor, New York, New York
     10017, to select a neutral pursuant to the following procedures:

          (a) The CPR shall submit to the parties a list of not less than five
          (5) candidates within fourteen (14) days after receipt of the request,
          along with a CURRICULUM VITAE for each candidate. No candidate shall
          be an employee, director, or shareholder of either party or any of
          their subsidiaries or affiliates.

          (b) Such list shall include a statement of disclosure by each
          candidate of any circumstances likely to affect his or her
          impartiality.

          (c) Each party shall number the candidates in order of preference
          (with the number one (1) signifying the greatest preference) and shall
          deliver the list to the CPR within seven (7) days following receipt of
          the list of candidates. If a party believes a conflict of interest
          exists regarding any of the candidates, that party shall provide a
          written explanation of the conflict to the CPR along with its list

                                       C-1
<Page>

          showing its order of preference for the candidates. Any party failing
          to return a list of preferences on time shall be deemed to have no
          order of preference.

          (d) If the parties collectively have identified fewer than three (3)
          candidates deemed to have conflicts, the CPR immediately shall
          designate as the neutral the candidate for whom the parties
          collectively have indicated the greatest preference. If a tie should
          result between two candidates, the CPR may designate either candidate.
          If the parties collectively have identified three (3) or more
          candidates deemed to have conflicts, the CPR shall review the
          explanations regarding conflicts and, in its sole discretion, may
          either (i) immediately designate as the neutral the candidate for whom
          the parties collectively have indicated the greatest preference, or
          (ii) issue a new list of not less than five (5) candidates, in which
          case the procedures set forth in subparagraphs 2(a) - 2(d) shall be
          repeated.

     3. No earlier than twenty-eight (28) days or later than fifty-six (56) days
     after selection, the neutral shall hold a hearing to resolve each of the
     issues identified by the parties. The ADR proceeding shall take place at a
     location agreed upon by the parties. If the parties cannot agree, the
     neutral shall designate a location other than the principal place of
     business of either party or any of their subsidiaries or affiliates.

     4. At least seven (7) days prior to the hearing, each party shall submit
     the following to the other party and the neutral:

          (a) a copy of all exhibits on which such party intends to rely in any
          oral or written presentation to the neutral;

          (b) a list of any witnesses such party intends to call at the hearing,
          and a short summary of the anticipated testimony of each witness;

          (c) a proposed ruling on each issue to be resolved, together with a
          request for a specific damage award or other remedy for each issue.
          The proposed rulings and remedies shall not contain any recitation of
          the facts or any legal arguments and shall not exceed one (1) page per
          issue.

          (d) a brief in support of such party's proposed rulings and remedies,
          provided that the brief shall not exceed twenty (20) pages. This page
          limitation shall apply regardless of the number of issues raised in
          the ADR proceeding.

     Each party shall be permitted to take up to a maximum of two (2)
     depositions of no more than five (5) hours each. Notwithstanding the
     foregoing, except as expressly set forth in subparagraphs 4(a) - 4(d) no
     further discovery shall be required or permitted by any means, including
     depositions, interrogatories, requests for admissions, or production of
     documents.

                                       C-2
<Page>

     5. The hearing shall be conducted on two (2) consecutive days and shall be
     governed by the following rules:

          (a) Each party shall be entitled to five (5) hours of hearing time to
          present its case. The neutral shall determine whether each party has
          had the five (5) hours to which it is entitled.

          (b) Each party shall be entitled, but not required, to make an opening
          statement, to present regular and rebuttal testimony, documents or
          other evidence, to cross-examine witnesses, and to make a closing
          argument. Cross-examination of witnesses shall occur immediately after
          their direct testimony, and cross-examination time shall be charged
          against the party conducting the cross-examination.

          (c) The party initiating the ADR shall begin the hearing and, if it
          chooses to make an opening statement, shall address not only issues it
          raised but also any issues raised by the responding party. The
          responding party, if it chooses to make an opening statement, also
          shall address all issues raised in the ADR. Thereafter, the
          presentation of regular and rebuttal testimony and documents, other
          evidence, and closing arguments shall proceed in the same sequence.

          (d) Except when testifying, witnesses shall be excluded from the
          hearing until closing arguments.

          (e) Settlement negotiations, including any statements made therein,
          shall not be admissible under any circumstances. Affidavits prepared
          for purposes of the ADR hearing also shall not be admissible. As to
          all other matters, the neutral shall have sole discretion regarding
          the admissibility of any evidence.

     6. Within seven (7) days following completion of the hearing, each party
     may submit to the other party and the neutral a post-hearing brief in
     support of its proposed rulings and remedies, provided that such brief
     shall not contain or discuss any new evidence and shall not exceed ten (10)
     pages. This page limitation shall apply regardless of the number of issues
     raised in the ADR proceeding.

     7. The neutral shall rule on each disputed issue within fourteen (14) days
     following completion of the hearing. Such ruling shall adopt in its
     entirety the proposed ruling and remedy of one of the parties on each
     disputed issue but may adopt one party's proposed rulings and remedies on
     some issues and the other party's proposed rulings and remedies on other
     issues. The neutral shall not issue any written opinion or otherwise
     explain the basis of the ruling.

     8. The neutral shall be paid a reasonable fee plus expenses. These fees and
     expenses, along with the reasonable legal fees and expenses of the
     prevailing party (including all

                                       C-3
<Page>

     expert witness fees and expenses) the fees and expenses of a court
     reporter, and any expenses for a hearing room, shall be paid as follows:

          (a) If the neutral rules in favor of one party on all disputed issues
          in the ADR, the losing party shall pay 100% of such fees and expenses.

          (b) If the neutral rules in favor of one party on some issues and the
          other party on other issues, the neutral shall issue with the rulings
          a written determination as to how such fees and expenses shall be
          allocated between the parties. The neutral shall allocate fees and
          expenses in a way that bears a reasonable relationship to the outcome
          of the ADR, with the party prevailing on more issues, or on issues of
          greater value or gravity, recovering a relatively larger share of its
          legal fees and expenses.

     9. The rulings of the neutral and the allocation of fees and expenses shall
     be binding, non-reviewable, and non-appealable, and may be entered as a
     final judgment in any court having jurisdiction.

     10. Except as provided in paragraph 9 or as required by law, the existence
     of the dispute, any settlement negotiations, the ADR hearing, any
     submissions (including exhibits, testimony, proposed rulings, and briefs),
     and the rulings shall be deemed Confidential Information. The neutral shall
     have the authority to impose sanctions for unauthorized disclosure of
     Confidential Information.

                                       C-4

<Page>

                       FIRST AMENDMENT TO LICENSE AGREEMENT

     This FIRST AMENDMENT TO LICENSE AGREEMENT (this "Amendment") is entered
into as of this 27th day of April, 2005 by and between Advanced Life Sciences
Holdings, Inc., a Delaware corporation ("ALS') and Abbott Laboratories, an
Illinois corporation ("Abbott") to amend the terms of that certain License
Agreement dated December 13, 2004 between Abbott and ALS (the "Agreement").

                                    BACKGROUND

     A.   The Agreement provides that certain amounts are to be paid by ALS
          to Abbott in the months of May and June 2005.

     B.   ALS has requested, and Abbott has agreed to a change in the payment
          terms for such amounts.

     C.   The parties wish to amend the Agreement to reflect the change in
          the payment terms.

     1.   INCORPORATION OF AGREEMENT. All capitalized terms which are not
defined herein shall have the same meanings as set forth in the Agreement,
and the Agreement, to the extent not inconsistent with this Amendment is
incorporated herein by this reference as though the same was set forth in its
entirety. To the extent any terms and provisions of the Agreement are
inconsistent with the amendment set forth in Paragraph 2 below, such terms
and provisions shall be deemed superseded hereby. Except as specifically set
forth herein, the Agreement shall remain in full force and effect and its
provisions shall be binding on the parties hereto.

     2.   AMENDMENT OF THE AGREEMENT. Paragraph 4.2(a) shall be replaced in
its entirety as follows:

          (a)  ALS shall pay to Abbott, as the purchase price for the
               Inventory to be purchased under this ARTICLE 4, the aggregate
               amount of Ten Million Dollars ($10,000,000), payable as
               follows: (a) Two Million Dollars ($2,000,000) upon the
               execution of this Agreement, (b) Eight Million Dollars
               ($8,000,000) on the earlier to occur of: (i) five (5) days
               after the closing of ALS' initial public offering of
               securities or, (ii) September 1, 2005. Abbott shall ship
               approximately a pro rata portion of the Inventory to ALS upon
               receipt of each of the foregoing payments (i.e. approximately
               twenty percent (20%) of the Inventory shall be shipped by
               Abbott upon receipt of the initial payment of Two Million
               Dollars ($2,000,000)) unless otherwise agreed by the parties
               in writing.

<Page>

     3.   EFFECTUATION. The amendment to the Agreement contemplated by this
Amendment shall be deemed effective as of the date first written above upon
the full execution of this Amendment and without any further action required
by the parties hereto. There are no conditions precedent or subsequent to the
effectiveness of this Amendment.

     4.   COUNTERPARTS. This Amendment may be executed in two or more
counterparts, each of which shall be deemed to be an original, but all of
which together shall constitute one and the same instrument. One or more
counterparts of this Amendment may be delivered by facsimile, with the
intention that delivery by such means shall have the same effect as delivery
of an original counterpart thereof.

     IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment
as of the date first above written.

ABBOTT LABORATORIES                             ADVANCED LIFE
                                                SCIENCES HOLDINGS, INC.

By: /s/ James L. Tyree                          By: /s/ Michael T. Flavin, M.D.
    ------------------                              ---------------------------
Name: James L. Tyree                            Name: Michael T. Flavin, M.D.
Its:  Vice President, Global Licensing/         Its:  Chairman and Chief
      New Business Development                        Executive Officer

<Page>

                      SECOND AMENDMENT TO LICENSE AGREEMENT

     This SECOND AMENDMENT TO THE LICENSE AGREEMENT (this "AMENDMENT") is
entered into as of this 1st day of August, 2005 by and between Advanced Life
Sciences Holdings, Inc., a Delaware corporation ("ALS") and Abbott
Laboratories, an Illinois corporation ("ABBOTT") to amend the terms of that
certain License Agreement dated December 13, 2004 between Abbott and ALS (the
"AGREEMENT").

                                   BACKGROUND

     A.   Abbott and ALS entered into the Agreement on December 13, 2004 (the
          "EFFECTIVE DATE").

     B.   The Agreement provides ALS with an exclusive worldwide license (except
          in Japan) to certain patent applications and patents relating to the
          Compounds.

     C.   Abbott has requested and ALS has agreed to delete all references to
          Compound B throughout the entire Agreement along with any associated
          rights or obligations.

     D.   The Agreement provides that certain amounts are to be paid by ALS to
          Abbott upon achieving certain milestone events.

     E.   Both ALS and Abbott desire to change the payment terms for those
          amounts due upon certain milestone events.

     F.   The Agreement provides that ALS shall pay to Abbott royalty payments
          on Net Sales of any Product.

     G.   ALS has requested and Abbott has agreed to change the amount of that
          certain royalty on Net Sales.

     H.   The parties wish to amend the Agreement to, among other things,
          reflect the changes outlined above.

     1. INCORPORATION OF THE AGREEMENT. All capitalized terms which are not
defined herein shall have the same meanings as set forth in the Agreement, and
the Agreement, to the extent not inconsistent with this Amendment, is
incorporated herein by this reference as though the same was set forth in its
entirety. To the extent any terms and provisions of the Agreement are
inconsistent with the amendments set forth in Paragraph 2 below, such terms and
provisions shall be deemed superseded hereby. Except as specifically set forth
herein, the Agreement shall remain in full force and effect and its provisions
shall be binding on the parties hereto.

     2. AMENDMENT OF THE AGREEMENT. The Agreement is hereby amended as follows:

        a. CHANGE IN DEFINITIONS.

                i.  Section 1.4 is hereby deleted in its entirety.

               ii.  All references to Compound B in Sections 1.5, 1.6, 1.10,
                    1.14, 1.15, and 1.16 are hereby deleted.

<Page>

               b.   CHANGE IN LICENSE GRANT. SECTION 2 of the Agreement is
                    hereby deleted in its entirety and shall be replaced with
                    the following:

                    "Subject to the terms and conditions of this Agreement,
                    Abbott hereby grants to ALS an Exclusive License in the
                    Territory, under Abbott Technology, for all Pharmaceutical
                    Uses, with the right to grant sublicenses pursuant to
                    SECTION 5.5 hereof, to (i) research, develop, make or have
                    made, Compound A and Product(s); (ii) apply for and obtain
                    Regulatory Approvals, all as may be required to manufacture
                    and commercialize Product(s); and (iii) register, use,
                    import/export, market, offer to sell and sell, Compound A
                    and Product(s)."

               c.   CHANGE IN REFERENCES TO COMPOUND B. All references to
                    Compound B in Sections 3, 6, and 7 any Exhibits attached to
                    the Agreement are hereby deleted along with any associated
                    rights or obligations.

               d.   CHANGE IN MILESTONE PAYMENTS. SECTION 6.1 of the Agreement
                    is hereby deleted in its entirety and shall be replaced with
                    the following:

                    "The milestone payments are independent, nonrefundable, and
                    are not creditable against any other amounts due under the
                    agreement:

<Table>
<Caption>
                    MILESTONE                                                                      PAYMENT
                    <S>                                                                         <C>
                    The earlier to occur of  October 31, 2005 or the commencement of             $2,000,000
                    clinical trials (administration to first patient) of Compound A by ALS

                    Submission of an NDA for Compound A for the United States. In the           $10,000,000
                    event that ALS submits an NDA for Compound A to the European Union
                    prior to submission in the United States, ALS shall pay to Abbott one
                    half (1/2) of the milestone due under this term upon submission to the
                    European Union and the balance of this milestone shall become due
                    upon submission of an NDA for Compound A in the United States.

                    Receipt of Regulatory Approval of Compound A in the United States.          $30,000,000
                    In the event that ALS receives Regulatory Approval of Compound A in
                    the European Union prior to receipt of Regulatory Approval in the
                    United States, ALS shall pay to Abbott one half (1/2) of the milestone
                    due under this term upon Regulatory Approval in the European Union
                    and the balance of this milestone shall become due upon receipt of
                    Regulatory Approval of Compound A in the United States.

                    Upon reaching Net Sales of $200,000,000 for the Product.                     $2,500,000

                    Upon reaching Net Sales of $400,000,000 for the Product.                     $5,000,000"
</Table>

               e.   CHANGE IN ROYALTY PAYMENTS. SECTION 6.2(a)(i) of the
                    Agreement is hereby deleted in its entirety and shall be
                    replaced with the following:

                    "nineteen percent (19%) on Net Sales of up to $100,000,000;
                    eighteen percent (18%) on Net Sales of $100,000,000.01 to
                    $200,000,000; and seveteen percent (17%) on Net Sales of
                    $200,000,000.01 and above, with respect to which,
                    but for the license granted hereunder, the manufacture, use
                    or sale of Product would infringe a Valid Claim in such
                    country, and"

     3.   EFFECTUATION. The amendment to the Agreement contemplated by this
          Amendment shall be deemed effective as of the date first written above
          upon the full execution of this Amendment and without any further
          action required by the parties hereto. There are no conditions
          precedent or subsequent to the effectiveness of this Amendment.

     4.   COUNTERPARTS. This Amendment may be executed in two or more
          counterparts, each of which shall be deemed to be an original, but all
          of which together shall constitute one and the same instrument. One or
          more counterparts of this Amendment may be delivered by facsimile,
          with the intention that delivery by such means shall have the same
          effect as delivery of an original counterpart thereof.

                            [SIGNATURE PAGE FOLLOWS]

<Page>

          [SIGNATURE PAGE TO SECOND AMENDMENT TO THE LICENSE AGREEMENT]

     IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment as
of the date first above written.

ABBOTT LABORATORIES                    ADVANCED LIFE SCIENCES HOLDINGS, INC.

By:    /s/ Jeffrey M. Leider, Ph.D.    By: /s/ Michael T. Flavin, Ph.D.
       -----------------------------       -------------------------------------
Name: Jeffrey M. Leider, Ph.D.         Name: Michael T. Flavin, Ph.D.
Its: President and Chief Operating     Its: Chairman and Chief Executive Officer
     Officer, Pharmaceutical Products
     Group<Page>

                                                                    Exhibit 10.1

                                4,500,000 SHARES

                          HITTITE MICROWAVE CORPORATION

                                  COMMON STOCK

                             UNDERWRITING AGREEMENT

                                                                   July 21, 2005
LEHMAN BROTHERS INC.
NEEDHAM & COMPANY, LLC
PIPER JAFFRAY & CO.
THOMAS WEISEL PARTNERS LLC
   As Representatives of the several
   Underwriters listed in SCHEDULE 1 hereto,
c/o Lehman Brothers Inc.
745 Seventh Avenue
New York, New York 10019

Ladies and Gentlemen:

     Hittite Microwave Corporation, a Delaware corporation (the "COMPANY"),
proposes to issue and sell 2,700,000 shares of the Company's Common Stock, par
value $0.01 per share (the "COMMON STOCK") to the several Underwriters listed in
SCHEDULE 1 hereto (the "UNDERWRITERS"), for whom you are acting as
representatives (the "REPRESENTATIVES"), and certain stockholders of the Company
named in SCHEDULE 2 hereto (each, a "SELLING STOCKHOLDER" and collectively, the
"SELLING STOCKHOLDERS") propose severally to sell an aggregate of 1,800,000
shares of Common Stock (such 4,500,000 shares of Common Stock being hereinafter
referred to as the "FIRM SHARES") to the Underwriters. In addition, the Company
proposes to grant to the Underwriters an option to purchase up to an additional
675,000 shares of Common Stock on the terms and for the purposes set forth in
Section 3 (the "OPTION SHARES"). The Firm Shares and the Option Shares, if
purchased, are hereinafter collectively called the "SHARES." This is to confirm
the agreement concerning the purchase of the Shares from the Company and the
Selling Stockholders by the Underwriters.

     SECTION 1.   REPRESENTATIONS, WARRANTIES AND AGREEMENTS OF THE COMPANY.
The Company represents, warrants and agrees that:

          (a)     A registration statement on Form S-1, and amendments thereto,
with respect to the Shares have (i) been prepared by the Company in conformity
with the requirements of the Securities Act of 1933, as amended (the "SECURITIES
ACT"), and the rules and regulations (the "RULES AND REGULATIONS") of the United
States Securities and Exchange Commission (the "COMMISSION") thereunder, (ii)
been filed with the

                                        1
<Page>

Commission under the Securities Act and (iii) become effective under the
Securities Act. Copies of such registration statement and each of the amendments
thereto have been delivered by the Company to the Representatives. As used in
this Agreement, "EFFECTIVE TIME" means the date and the time as of which such
registration statement, or the most recent post-effective amendment thereto, if
any, was declared effective by the Commission; "EFFECTIVE DATE" means the date
of the Effective Time; "PRELIMINARY PROSPECTUS" means each prospectus included
in such registration statement, or amendments thereof, before it became
effective under the Securities Act and any prospectus filed with the Commission
by the Company with the consent of the Representatives pursuant to Rule 424(a)
of the Rules and Regulations; "REGISTRATION STATEMENT" means such registration
statement, as amended at the Effective Time, including all information contained
in the final prospectus filed with the Commission pursuant to Rule 424(b) of the
Rules and Regulations in accordance with Section 6(a) hereof and deemed to be a
part of the Registration Statement as of the Effective Time pursuant to Rule
430A of the Rules and Regulations; and "PROSPECTUS" means such final prospectus,
as first filed with the Commission pursuant to paragraph (1) or (4) of Rule
424(b) of the Rules and Regulations. If the Company has filed an abbreviated
registration statement to register additional shares of Common Stock pursuant to
Rule 462(b) under the Securities Act (the "RULE 462 REGISTRATION STATEMENT"),
then any reference herein to the term "REGISTRATION STATEMENT" shall be deemed
to include such Rule 462 Registration Statement. The Commission has not issued
any order preventing or suspending the use of any Preliminary Prospectus.

          (b)     The Registration Statement conforms, and the Prospectus and
any further amendments or supplements to the Registration Statement or the
Prospectus will, when they become effective or are filed with the Commission, as
the case may be, conform in all material respects to the requirements of the
Securities Act and the Rules and Regulations, and the Registration Statement and
any amendment thereto does not and will not, as of the applicable effective
date, contain an untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements therein
not misleading, and the Prospectus and any amendment or supplement thereto will
not, as of the applicable filing date and each Delivery Date (as defined below),
contain an untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein, in
the light of the circumstances under which they were made, not misleading;
provided that no representation, warranty or agreement is made as to information
contained in or omitted from the Registration Statement (or any amendment
thereto) or the Prospectus (or any amendment or supplement thereto) in reliance
upon and in conformity with written information furnished to the Company through
the Representatives by or on behalf of any Underwriter specifically for
inclusion therein.

          (c)     The Company and each of its subsidiaries have been duly
incorporated and are validly existing as corporations in good standing under the
laws of their respective jurisdictions of incorporation, are duly qualified to
do business and are in good standing as foreign corporations in each
jurisdiction in which their respective

                                        2
<Page>

ownership or lease of property or the conduct of their respective businesses
requires such qualification, except where the failure to be so qualified or in
good standing would not have a material adverse effect on the business,
condition (financial or otherwise), stockholders' equity, prospects or results
of operations of the Company and its subsidiaries, taken as a whole (a "MATERIAL
ADVERSE EFFECT"), and have all power and authority necessary to own or hold
their respective properties and to conduct the businesses in which they are
engaged. None of the subsidiaries of the Company is a "significant subsidiary",
as such term is defined in Rule 405 of the Rules and Regulations.

          (d)     The Company has an authorized capitalization as set forth in
the Prospectus. All of the issued shares of capital stock of the Company have
been duly and validly authorized and issued, are fully paid and non-assessable,
were issued in compliance with federal and state securities laws, and conform to
the description thereof contained in the Prospectus. All of the Company's
options, warrants and other rights to purchase or exchange any securities for
shares of the Company's capital stock have been duly and validly authorized and
issued, were issued in compliance with federal and state securities laws, and
conform to the description thereof contained in the Prospectus. All of the
issued shares of capital stock of each subsidiary of the Company have been duly
and validly authorized and issued and are fully paid and non-assessable and
(except for directors' qualifying shares for any foreign subsidiaries) are owned
directly or indirectly by the Company, free and clear of all liens,
encumbrances, equities or claims, except for the security interest granted in
connection with the credit facility as described in the Prospectus. None of such
securities were issued in violation of preemptive or other similar rights
arising by operation of law, under the charter and bylaws of the Company or any
of its subsidiaries or under any agreement to which the Company or any of its
subsidiaries is a party or otherwise.

          (e)     The Shares to be issued and sold by the Company to the
Underwriters hereunder have been duly and validly authorized and, when issued
and delivered against payment therefor in accordance with this Agreement, will
be duly and validly issued, fully paid and non-assessable; and the Shares will
conform to the descriptions thereof contained in the Prospectus. Upon payment
for and delivery of the Shares to be sold by the Company pursuant to this
Agreement, the Underwriters will acquire good and valid title to such Shares, in
each case free and clear of all liens, encumbrances, equities, preemptive
rights, subscription rights, other rights to purchase, voting or transfer
restrictions and other similar claims.

          (f)     The Company has all requisite corporate power and authority to
execute, deliver and perform its obligations under this Agreement. This
Agreement has been duly and validly authorized, executed and delivered by the
Company.

          (g)     The execution, delivery and performance by the Company of this
Agreement and the consummation by the Company of the transactions contemplated
hereby (the "TRANSACTIONS") will not (i) conflict with or result in a breach or
violation of any of the terms or provisions of, impose any material lien, charge
or encumbrance upon

                                        3
<Page>

any property or assets of the Company and its subsidiaries, or constitute a
default under, any indenture, mortgage, deed of trust, loan agreement or other
material agreement, license or instrument to which the Company or any of its
subsidiaries is a party or by which the Company or any of its subsidiaries is
bound or to which any of the property or assets of the Company or any of its
subsidiaries is subject, (ii) result in any violation of the provisions of the
charter or bylaws of the Company or any of its subsidiaries or (iii) result in
any material violation of any statute or any order, rule or regulation of any
court or governmental agency or body having jurisdiction over the Company or any
of its subsidiaries or any of their properties or assets; and except for the
registration of the Shares under the Securities Act and such consents,
approvals, authorizations, registrations or qualifications as may be required
under the Securities Exchange Act of 1934, as amended (the "EXCHANGE ACT"),
applicable state or foreign securities laws in connection with the purchase and
distribution of the Shares by the Underwriters, the rules of the Nasdaq Stock
Market, Inc. and the rules of the National Association of Securities Dealers,
Inc. ("NASD"), no consent, approval, authorization or order of, or filing or
registration with, any such court or governmental agency or body is required for
the execution, delivery and performance by the Company of this Agreement or any
of the other documents to be entered into by the Company in connection with the
Transactions, the compliance by the Company with all of the applicable
provisions of this Agreement, and the consummation by the Company of the
Transactions, except for such consents, approvals, authorizations, orders,
filings or registrations as have been obtained or made.

          (h)     Except as described in the Prospectus, there are no contracts,
agreements or understandings between the Company and any person granting such
person the right to require the Company to file a registration statement under
the Securities Act with respect to any securities of the Company owned or to be
owned by such person or to require the Company to include such securities in the
securities registered pursuant to the Registration Statement or in any
securities registered or to be registered pursuant to any other registration
statement filed by or required to be filed by the Company under the Securities
Act. The holders of outstanding shares of the Company's capital stock are not
entitled to preemptive or other rights to subscribe for the Shares to be sold by
the Company pursuant to this Agreement nor, to the Company's knowledge, the
Shares to be sold by the Selling Stockholders pursuant to this Agreement. Except
as disclosed in the Prospectus, upon completion of the offering, no options,
warrants or other rights to purchase, agreements or other obligations to issue,
or rights to convert any obligations into or exchange any securities for, shares
of capital stock of, or ownership interests in, the Company will be outstanding
(other than securities that may be granted by the Company after July 15, 2005
pursuant to the Company's 2005 Stock Incentive Plan).

          (i)     The Company has not sold or issued any shares of Common Stock
during the six-month period preceding the date of the Prospectus, including any
sales pursuant to Rule 144A, or Regulations D or S, under the Securities Act,
other than shares issued pursuant to employee benefit plans, equity plans or
other employee compensation plans, or pursuant to outstanding options, rights or
warrants.

                                        4
<Page>

          (j)     Neither the Company nor any of its subsidiaries has sustained,
since the date of the latest audited financial statements included in the
Prospectus, any material loss or interference with its business from fire,
explosion, flood or other calamity, whether or not covered by insurance, or from
any labor dispute or court or governmental action, order or decree, otherwise
than as set forth or contemplated in the Prospectus; and, since such date, there
has not been any change in the capital stock (other than (i) shares issued
pursuant to employee benefit plans, equity plans or other employee compensation
plans, each of which plans is described in the Prospectus, (ii) the repurchase
by the Company of 5,000 shares of Common Stock that occurred on or about June
24, 2005 and (iii) repurchases of shares of Common Stock issued to or held by
employees of the Company pursuant to the terms of employee stock repurchase
agreements providing for the Company's right of first refusal thereunder) or
long-term debt of the Company or any of its subsidiaries or any material adverse
change, or any development involving a prospective material adverse change, in
or affecting the general affairs, management, consolidated financial position,
stockholders' equity, results of operations, business or prospects of the
Company and its subsidiaries, taken as a whole, otherwise than as set forth or
contemplated in the Prospectus.

          (k)     Neither the Company nor any of its subsidiaries has any
off-balance sheet arrangement (as defined in Item 303(a)(4) of Regulation S-K)
or material liability of any nature (matured or not matured, fixed or
contingent) to, or any financial interest in, any third party or unconsolidated
entity other than as set forth in the Prospectus. The financial statements
(including the related notes and supporting schedules) filed as part of the
Registration Statement or included in the Prospectus comply as to form in all
material respects with the requirements of Regulation S-X under the Securities
Act and present fairly the financial condition, results of operations and cash
flows of the entities purported to be shown thereby, at the dates and for the
periods indicated, and have been prepared in conformity with accounting
principles generally accepted in the United States applied on a consistent basis
throughout the periods involved. The pro forma financial information included in
the Registration Statement and Prospectus has been prepared in accordance with
the applicable requirements of the Securities Act, the Rules and Regulations and
the official pronouncements, if any, of the Emerging Issues Task Force, and
includes all adjustments necessary to present fairly the pro forma financial
position of the Company presented therein at the date indicated and the results
of its operations for the respective periods specified. The other financial and
accounting data, operating data and statistical information and data that is
financial in nature included in the Prospectus is presented fairly and has been
prepared on a basis consistent in all material respects with the financial
statements filed as part of the Registration Statement and included in the
Prospectus and the books and records of the Company.

          (l)     PricewaterhouseCoopers LLP, whose report on certain financial
statements of the Company is included in the Prospectus, are and have been
independent public accountants as required by the Securities Act and the Rules
and Regulations during the period covered by the financial statements on which
they reported. Except as

                                        5
<Page>

pre-approved in accordance with the requirements set forth in Section 10A of the
Exchange Act (to the extent applicable to the Company), PricewaterhouseCoopers
LLP has not engaged in any "prohibited activities" (as defined in Section 10A of
the Exchange Act) on behalf of the Company.

          (m)     The Company and each of its subsidiaries have good and
marketable title in fee simple to all real property and good and marketable
title to all personal property owned by them, in each case free and clear of all
liens, encumbrances and defects, except (i) such as are described in the
Prospectus or (ii) such as do not materially affect the value of such property
and do not materially interfere with the use made and proposed to be made of
such property by the Company and its subsidiaries; and all real property and
assets held under lease by the Company and its subsidiaries are held by them
under valid, subsisting and enforceable leases, with such exceptions as are not
material and do not interfere with the use made and proposed to be made of such
property and buildings by the Company and its subsidiaries.

          (n)     The Company and each of its subsidiaries have all material
permits, licenses, franchises, certificates of need and other approvals or
authorizations of governmental or regulatory authorities ("PERMITS") as are
necessary under applicable law to own their properties and to conduct their
businesses in the manner described in the Prospectus; each of the Company and
its subsidiaries has fulfilled and performed all of its material obligations
with respect to the Permits, and no event has occurred which allows, or after
notice or lapse of time would allow, revocation or termination thereof or result
in any other material impairment of the rights of the holder of any such
Permits.

          (o)     The Company and each of its subsidiaries carry, or are covered
by, insurance from insurers of recognized financial responsibility in such
amounts and covering such risks as is adequate for the value of their respective
properties and as is customary for companies engaged in similar businesses in
similar industries, and all policies of insurance insuring the Company and each
of its subsidiaries or their respective businesses, assets, employees, officers
and directors are in full force and effect in all material respects.

          (p)     Except as described in the Prospectus, there are no legal or
governmental proceedings pending to which the Company or any of its subsidiaries
is a party or of which any property or assets of the Company or any of its
subsidiaries is the subject; and, to the best of the Company's knowledge, no
such proceeding is threatened or contemplated by governmental authorities or
threatened by others. The statements contained in the Prospectus under the
captions "Risk Factors--If we fail to comply with export control regulations we
could be subject to substantial fines, or other sanctions" and
"Business--Litigation" constitute a fair and accurate summary in all material
respects of the subject matter thereof.

          (q)     The Company and each of its subsidiaries own or possess, or
can acquire on reasonable terms, adequate rights to use all material patents,
patent applications, inventions, trade secrets, trademarks, service marks, trade
names, domain

                                        6
<Page>

names, trademark registrations, service mark registrations, copyrights,
know-how, manufacturing processes, formulae, licenses and other rights
(collectively, the "INTELLECTUAL PROPERTY") necessary for the conduct of their
respective businesses as now conducted and as proposed to be conducted as
described in the Prospectus; and the expected expiration of any Intellectual
Property would not have a Material Adverse Effect. Neither the Company nor any
of its subsidiaries has received any notice of any claim of any such
infringement or violation that would require disclosure in the Prospectus.
Except as described in the Prospectus, no action, suit, arbitration, or legal,
administrative or other proceeding or investigation is pending, or, to the
Company's knowledge, is threatened, that involves the Intellectual Property. The
Intellectual Property of the Company and each of its subsidiaries does not
infringe or conflict with any right or valid and enforceable patent of any third
party, or any discovery, invention, product or process which is the subject of a
valid patent application filed by any third party of which the Company is aware.
The Company is not subject to any judgment, order, writ, injunction or decree of
any court or any federal, state, local, foreign or other governmental
department, commission, board, bureau, agency or instrumentality, domestic or
foreign, or any arbitrator, nor has it entered into or is a party to any
contract that restricts or impairs the use of any Intellectual Property in a
manner that would reasonably be expected to have a Material Adverse Effect. The
security measures taken and the protection afforded by the Company and each of
its subsidiaries to its trade secrets and other material non-patented technology
are substantially similar to the security measures taken and the protection
afforded by similarly situated companies in the Company's industry. Except as
disclosed in the Prospectus, to the Company's knowledge, no person is infringing
or violating the Company's rights with respect to the Intellectual Property.

          (r)     There are no contracts or other documents that are required to
be described in the Prospectus or filed as exhibits to the Registration
Statement by the Securities Act or by the Rules and Regulations that have not
been described in the Prospectus or filed as exhibits to the Registration
Statement.

          (s)     No relationship, direct or indirect, exists between or among
the Company or any subsidiary on the one hand, and the directors, officers,
stockholders, customers or suppliers of the Company on the other hand, that is
required to be described in the Prospectus that is not so described. Since the
date on which the Registration Statement was first filed with the Commission,
the Company has not, directly or indirectly, including through any subsidiary,
extended or maintained credit, or arranged for the extension of credit, or
renewed an extension of credit, in the form of a personal loan to or for any of
its directors or executive officers.

          (t)     No material labor disturbance by the employees of the Company
or any of its subsidiaries exists or, to the knowledge of the Company, is
imminent.

          (u)     The Company and each of its subsidiaries is in compliance in
all material respects with all presently applicable provisions of the Employee
Retirement Income Security Act of 1974, as amended, including the regulations
and published

                                        7
<Page>

interpretations thereunder ("ERISA"); no "REPORTABLE EVENT" (as defined in
ERISA) has occurred with respect to any "PENSION PLAN" (as defined in ERISA) for
which the Company and each of its subsidiaries would be reasonably likely to
have any liability; the Company and each of its subsidiaries has not incurred
and does not expect to incur liability under (i) Title IV of ERISA with respect
to termination of, or withdrawal from, any "PENSION PLAN" or (ii) Sections 412
or 4971 of the Internal Revenue Code of 1986, as amended, including the
regulations and published interpretations thereunder (the "CODE"); and each
"PENSION PLAN" for which the Company and each of its subsidiaries would have any
liability that is intended to be qualified under Section 401(a) of the Code is
so qualified in all material respects and nothing has occurred, whether by
action or by failure to act, which would reasonably be expected to cause the
loss of such qualification.

          (v)     The Company and each of its subsidiaries have filed all
foreign, federal, state and local income and franchise tax returns required to
be filed through the date hereof and have paid all taxes due thereon (except
such taxes as the Company or any of its subsidiaries is challenging in good
faith), except where the failure to file any such return or to pay any such tax
would not have a Material Adverse Effect, and no tax deficiency has been
determined adversely to the Company or any of its subsidiaries which has had
(nor does the Company have any knowledge of any tax deficiency which, if
determined adversely to the Company or any of its subsidiaries, would reasonably
be expected to have) a Material Adverse Effect.

          (w)     Since the date as of which information is given in the
Prospectus through the date hereof, and except as may otherwise be disclosed in
the Prospectus, the Company has not (i) issued or granted any securities other
than shares or stock options issued or granted pursuant to employee benefit
plans, equity plans or other employee compensation plans, or pursuant to
outstanding options, rights or warrants, (ii) incurred any liability or
obligation, direct or contingent, other than liabilities and obligations which
were incurred in the ordinary course of business, (iii) entered into any
material transaction not in the ordinary course of business or (iv) declared or
paid any dividend on its capital stock. The cash dividend in the aggregate
amount of approximately $34.2 million payable immediately prior to the First
Delivery Date (A) has been duly and validly authorized by all necessary
corporate action on the part of the Company and its stockholders, (B) has not
resulted and will not result in a breach or violation of the terms or provisions
of any material agreement, license or instrument to which the Company or any of
its subsidiaries is a party or by which the Company or any of its subsidiaries
is bound or to which any of the property or assets of the Company or any of its
subsidiaries is subject, (C) has not resulted and will not result in any
violation of the provisions of the charter or bylaws of the Company or any of
its subsidiaries and (D) has not resulted and will not result in any material
violation of any statute or any order, rule or regulation of any court or
governmental agency or body having jurisdiction over the Company or any of its
subsidiaries or any of their properties or assets. The Prospectus contains a
fair and accurate summary in all material respects of such cash dividend under
the heading "Dividend Policy."

                                        8
<Page>

          (x)     The Company and each of its subsidiaries (i) makes and keeps
accurate books and records and (ii) maintains a system of internal accounting
controls that provides reasonable assurance that (A) transactions are executed
in accordance with management's authorization, (B) transactions are recorded as
necessary to permit preparation of its financial statements in conformity with
accounting principles generally accepted in the United States and to maintain
accountability for its assets, (C) access to its assets is permitted only in
accordance with management's authorization, (D) the recorded accountability for
its assets is compared with existing assets at reasonable intervals and (E)
material information related to such controls is reported or otherwise made
known to the Company's Chief Executive Officer and Chief Financial Officer.

          (y)     Neither the Company nor any of its subsidiaries (i) is in
violation of its charter or bylaws (or similar organizational documents), (ii)
is in default, and no event has occurred which, with notice or lapse of time or
both, would constitute such a default, in the due performance or observance of
any term, covenant or condition contained in any indenture, mortgage, deed of
trust, loan agreement or other agreement or instrument to which it is a party or
by which it is bound or to which any of its properties or assets is subject or
(iii) is in violation of any law, ordinance, governmental rule, regulation or
court decree to which it or its property or assets is subject, except in the
case of clause (ii) or (iii) for such violations, defaults and events as would
not have a Material Adverse Effect.

          (z)     Neither the Company nor any of its subsidiaries, nor any
director, officer, employee or agent of the Company or any of its subsidiaries
or any stockholder thereof acting on behalf of the Company or any of its
subsidiaries, has used any corporate funds for any unlawful contribution, gift,
entertainment or other unlawful expense relating to political activity; made any
direct or indirect unlawful payment to any foreign or domestic government
official or employee from corporate funds; violated or is in violation of any
provision of the Foreign Corrupt Practices Act of 1977; or made any bribe,
rebate, payoff, influence payment, kickback or other unlawful payment.

          (aa)    The Company and each of its subsidiaries (i) are, and at all
prior times were, in compliance with any and all applicable foreign, federal,
state and local laws, regulations, ordinances, rules, orders, judgments,
decrees, permits or other legal requirements relating to the protection of human
health and safety, the environment, natural resources or hazardous or toxic
substances or wastes, pollutants or contaminants ("ENVIRONMENTAL LAWS"), which
compliance includes obtaining, maintaining and complying with all permits and
authorizations and approvals required by Environmental Laws to conduct their
respective businesses and (ii) have not received notice of any actual or
potential liability under Environmental Laws for the investigation or
remediation of any disposal or release of hazardous or toxic substances or
wastes, pollutants or contaminants, except in the case of clause (i) or (ii)
where such non-compliance with or liability under Environmental Laws would not,
individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect; and neither the Company nor any of its subsidiaries has been
named as a "potentially responsible party" under the Comprehensive Environmental
Response, Compensation, and Liability Act of

                                        9
<Page>

1980, as amended, or any other similar Environmental Law, except with respect to
any matters, individually or in the aggregate, that would not have a Material
Adverse Effect. Except as described in the Prospectus, (i) none of the Company
and its subsidiaries is a party to any proceeding under Environmental Laws in
which a governmental authority is also a party, other than such proceedings
regarding which the Company believes no monetary penalties of $100,000 or more
will be imposed, and (ii) none of the Company and its subsidiaries anticipates
material capital expenditures relating to Environmental Laws.

          (bb)    Neither the Company nor any of its subsidiaries is, nor, as of
the applicable Delivery Date (as defined below) and after giving effect to the
Transactions and the application of the net proceeds therefrom as described in
the Prospectus, will be, an "investment company" or a company "controlled" by an
"investment company" within the meaning of the Investment Company Act of 1940,
as amended, and the rules and regulations of the Commission thereunder.

          (cc)    The Company and each of its subsidiaries have established and
maintain disclosure controls and procedures (as such term is defined in Rule
13a-15 under the Exchange Act). Such disclosure controls and procedures are
designed to ensure that information required to be disclosed by the Company in
the reports that it files or submits under the Exchange Act is recorded,
processed, summarized and reported, within the time periods specified in the
Commission's rules and forms, and include, without limitation, controls and
procedures designed to ensure that information required to be disclosed by the
Company in the reports that it files or submits under the Exchange Act is
accumulated and communicated to the Company's management, including its
principal executive and principal financial officers, or persons performing
similar functions, as appropriate to allow timely decisions regarding required
disclosure. Such disclosure controls and procedures are effective in all
material respects to perform the functions for which they were established.

          (dd)    Since the date of the most recent balance sheet of the Company
and its consolidated subsidiaries audited by PricewaterhouseCoopers LLP and
reviewed by the audit committee of the board of directors of the Company, the
Company has not been advised of and is not aware of (i) any significant
deficiency or material weaknesses in the design or operation of internal control
over financial reporting that is reasonably likely to adversely affect the
Company's ability to record, process, summarize and report financial data or any
material weaknesses in internal controls; or (ii) any fraud that involves
management or other employees who have a significant role in the Company's
internal control over financial reporting.

          (ee)    Since the date of the most recent balance sheet of the Company
and its consolidated subsidiaries reviewed or audited by PricewaterhouseCoopers
LLP, there has been no change in the Company's internal control over financial
reporting that has materially affected, or is reasonably likely to materially
affect, the Company's internal control over financial reporting.

                                       10
<Page>

          (ff)    The Company is in material compliance with all applicable
provisions of the Sarbanes-Oxley Act of 2002, including the rules and
regulations of the Commission promulgated thereunder, and as of the date hereof,
the Company is aware of no reason that its quarterly report on Form 10-Q for the
fiscal quarter ended June 30, 2005 would not be accompanied by the
certifications required to be filed or submitted by the Company's chief
executive officer and chief financial officer pursuant to the Sarbanes-Oxley Act
and the rules and regulations promulgated thereunder.

          (gg)    To the extent permitted by the terms of any option issued
under the Company's Amended and Restated 1996 Stock Option Plan or 2005 Stock
Incentive Plan (collectively, the "PLANS"), the Company (i) has exercised its
right to cause the holder of such option, or any shares of Common Stock issued
under such option, as the case may be, to be bound not to engage in any of the
transactions prohibited by the terms of the Lock-up Letter (as defined in
Section 6(j) below) for a period of 180 days after the date of the Prospectus
(the "PLAN LOCK-UP") and (ii) has imposed a stop-transfer instruction with the
Company's transfer agent with respect to the Plan Lock-up.

          (hh)    Except as disclosed in the Prospectus, the holders of at least
98% of the outstanding shares of the Company's capital stock as of the date
hereof, including securities convertible into or exercisable or exchangeable for
shares of capital stock as of the date hereof, have executed Lock-up Letters (as
described in Section 6(j)).

          (ii)    The Company has not distributed and, prior to the later to
occur of any Delivery Date and completion of the distribution of the Shares,
will not distribute, any offering material in connection with the offering and
sale of the Shares other than the Preliminary Prospectus and the Prospectus.

          (jj)    The Company has not taken and will not take, directly or
indirectly, any action designed to or which has constituted or which might
reasonably be expected to cause or result in the stabilization or manipulation
of the price of any security of the Company to facilitate the sale or resale of
the Shares.

          (kk)    The Shares have been approved for quotation, subject to notice
of issuance, on The Nasdaq National Market.

     SECTION 2.   REPRESENTATIONS, WARRANTIES AND AGREEMENTS OF THE SELLING
STOCKHOLDERS. Each Selling Stockholder severally represents, warrants and agrees
that:

          (a)     The Selling Stockholder has, and immediately prior to the
First Delivery Date the Selling Stockholder will have, good and valid title to
the Shares to be sold by the Selling Stockholder hereunder on such date, free
and clear of all liens, encumbrances, equities or claims (except such as may
arise under this Agreement, the Custody Agreement and the Power of Attorney,
each as defined below); and upon delivery of such Shares and payment therefor
pursuant hereto, good and valid title to such Shares, free and clear of all
liens, encumbrances, equities or claims, will pass to the several Underwriters.

                                       11
<Page>

          (b)     The Selling Stockholder has placed in custody under a custody
agreement (the "CUSTODY AGREEMENT" and, together with all other similar
agreements executed by the other Selling Stockholders, the "CUSTODY AGREEMENTS")
with the Company, as custodian (the "CUSTODIAN"), for delivery under this
Agreement, certificates in negotiable form (with signature guaranteed by a
commercial bank or trust company having an office or correspondent in the United
States or a member firm of the New York or American Stock Exchanges)
representing the Shares to be sold by the Selling Stockholder hereunder.

          (c)     The Selling Stockholder has duly and irrevocably executed and
delivered a power of attorney (the "POWER OF ATTORNEY" and, together with all
other similar agreements executed by the other Selling Stockholders, the "POWERS
OF ATTORNEY") appointing Stephen G. Daly and William W. Boecke, or either of
them, as attorneys-in-fact, with full power of substitution, and with full
authority (exercisable by any one or more of them) to execute and deliver this
Agreement and to take such other action as may be necessary or desirable to
carry out the provisions hereof on behalf of the Selling Stockholder.

          (d)     The Selling Stockholder has full right, power and authority to
enter into this Agreement, the Power of Attorney and the Custody Agreement; the
execution, delivery and performance of this Agreement, the Power of Attorney and
the Custody Agreement by the Selling Stockholder, the compliance by the Selling
Stockholder with all of the applicable provisions of this Agreement, the Power
of Attorney and the Custody Agreement, and the consummation by each Selling
Stockholder of the transactions contemplated hereby and thereby will not (i)
result in a breach or violation of any of the terms or provisions of, or
constitute a default under, any indenture, mortgage, deed of trust, loan
agreement or other agreement or instrument to which the Selling Stockholder is a
party or by which the Selling Stockholder is bound or to which any of the
property or assets of the Selling Stockholder is subject, except where such
breach, violation or default would not adversely affect the Selling
Stockholder's ability to perform its obligations under this Agreement, the Power
of Attorney and the Custody Agreement, (ii) if the Selling Stockholder is not a
natural person, result in any violation of the provisions of the charter or
bylaws, articles of partnership, deed of trust or other organization documents
of the Selling Stockholder or (iii) result in any material violation of any
statute or any order, rule or regulation of any court or governmental agency or
body having jurisdiction over the Selling Stockholder or any of its properties
or assets; and, except for the registration of the Shares under the Securities
Act and such consents, approvals, authorizations, registrations or
qualifications as may be required under the Exchange Act, applicable state or
foreign securities laws in connection with the purchase and distribution of the
Shares by the Underwriters, the rules of the Nasdaq Stock Market, Inc. or the
rules of the NASD, no consent, approval, authorization or order of, or filing or
registration with, any such court or governmental agency or body is required for
the execution, delivery and performance of this Agreement, the Power of Attorney
or the Custody Agreement by the Selling Stockholder, the compliance by the
Selling Stockholder with all of the applicable provisions of this Agreement, the
Power of

                                       12
<Page>

Attorney and the Custody Agreement, and the consummation by the Selling
Stockholder of the transactions contemplated hereby and thereby, except for such
consents, approvals, authorizations, orders, filings or registrations as have
been obtained or made.

          (e)     To the extent that any statements or omissions made in the
Registration Statement, any Preliminary Prospectus, the Prospectus or any
amendment or supplement thereto are made in reliance upon and in conformity with
written information furnished to the Company by such Selling Stockholder
expressly for use therein, such Preliminary Prospectus and the Registration
Statement did not, and the Prospectus and any further amendments or supplements
to the Registration Statement and the Prospectus, when they become effective or
are filed with the Commission, as the case may be, will not, contain any untrue
statement of a material fact or omit to state any material fact required to be
stated therein or necessary to make the statements therein not misleading.

          (f)     The Selling Stockholder is not prompted to sell the Shares by
any information concerning the Company that is not set forth in the Registration
Statement and the Prospectus.

          (g)     The Selling Stockholder has not taken and will not take,
directly or indirectly, any action designed to or which has constituted or which
might reasonably be expected to cause or result in the stabilization or
manipulation of the price of any security of the Company to facilitate the sale
or resale of the Shares.

          (h)     This Agreement has been duly authorized (if applicable),
executed and delivered by or on behalf of the Selling Stockholder.

     SECTION 3.   PURCHASE OF THE SHARES BY THE UNDERWRITERS. On the basis of
the representations and warranties contained in, and subject to the terms and
conditions of, this Agreement, the Company agrees to sell 2,700,000 shares of
the Firm Shares, and each Selling Stockholder hereby agrees to sell the number
of shares of the Firm Shares set forth opposite its name in SCHEDULE 2 hereto,
to the several Underwriters, and each of the Underwriters, severally and not
jointly, agrees to purchase the number of shares of the Firm Shares set forth
opposite that Underwriter's name in SCHEDULE 1 hereto. Each Underwriter shall be
obligated to purchase from the Company and from each Selling Stockholder that
number of Firm Shares obtained by multiplying 2,700,000 Firm Shares, in the case
of the Company, and the number of Firm Shares set forth opposite the name of
such Selling Stockholder in SCHEDULE 2 hereto, in the case of a Selling
Stockholder, in each case by a fraction the numerator of which is the number of
Firm Shares set forth opposite the name of such Underwriter in SCHEDULE 1 hereto
and the denominator of which is the total number of Firm Shares. The respective
purchase obligations of the Underwriters with respect to the Firm Shares shall
be rounded among the Underwriters to avoid fractional shares, as the
Representatives may determine.

In addition, the Company grants to the Underwriters an option to purchase up to
675,000 shares of Option Shares. Such option is granted for the purpose of
covering over-allotments in the sale of Firm Shares and is exercisable as
provided in Section 5 hereof.

                                       13
<Page>

Shares of Option Shares shall be purchased severally for the account of the
Underwriters in proportion to the number of shares of Firm Shares set forth
opposite the name of such Underwriters in SCHEDULE 1 hereto. The respective
purchase obligations of each Underwriter with respect to the Option Shares shall
be adjusted by the Representatives so that no Underwriter shall be obligated to
purchase Option Shares other than in 100 share amounts.

The price of both the Firm Shares and any Option Shares shall be $15.81 per
share.

The Company and the Selling Stockholders shall not be obligated to deliver any
of the Shares to be delivered on any Delivery Date, except upon payment for all
the Shares to be purchased on such Delivery Date as provided herein.

     SECTION 4.   OFFERING OF SHARES BY THE UNDERWRITERS. Upon authorization
by the Representatives of the release of the Firm Shares, the several
Underwriters propose to offer the Firm Shares for sale upon the terms and
conditions set forth in the Prospectus.

     SECTION 5.   DELIVERY OF AND PAYMENT FOR THE SHARES. Delivery of and
payment for the Firm Shares shall be made at the offices of Foley Hoag LLP,
World Trade Center West, 155 Seaport Boulevard, Boston, Massachusetts 02210, at
10:00 A.M., New York City time, on the fourth full business day following the
date of this Agreement or at such other date, time or place as shall be
determined by agreement between the Representatives and the Company. This date
and time are sometimes referred to as the "FIRST DELIVERY DATE." On the First
Delivery Date, the Company and the Selling Stockholders shall deliver or cause
to be delivered certificates representing the Firm Shares to the Representatives
for the account of each Underwriter against payment to or upon the order of the
Company and the Selling Stockholders of the purchase price by wire transfer in
immediately available funds. Time shall be of the essence, and delivery at the
time and place specified pursuant to this Agreement is a further condition of
the obligation of each Underwriter hereunder. Upon delivery, the Firm Shares
shall be registered in such names and in such denominations as the
Representatives shall request in writing not less than two full business days
prior to the First Delivery Date. For the purpose of expediting the checking and
packaging of the certificates for the Firm Shares, the Company and the Selling
Stockholders shall make the certificates representing the Firm Shares available
for inspection by the Representatives in Boston, Massachusetts, not later than
2:00 P.M., New York City time, on the business day prior to the First Delivery
Date.

The option granted in Section 3 will expire 30 days after the date of this
Agreement and may be exercised in whole or in part from time to time by written
notice being given to the Company by the Representatives. Such notice shall set
forth the aggregate number of shares of Option Shares as to which the option is
being exercised, the names in which the shares of Option Shares are to be
registered, the denominations in which the shares of Option Shares are to be
issued and the date and time, as determined by the Representatives, when the
shares of Option Shares are to be delivered; provided, however, that this date
and time shall not be earlier than the First Delivery Date nor earlier than the
second business day after the date on which the option shall have been

                                       14
<Page>

exercised nor later than the fifth business day after the date on which the
option shall have been exercised. The date and time the shares of Option Shares
are delivered are sometimes referred to as a "SUBSEQUENT DELIVERY DATE" and the
First Delivery Date and any Subsequent Delivery Date are sometimes each referred
to as a "DELIVERY DATE". Delivery of and payment for the Option Shares shall be
made at the place specified in the first sentence of the first paragraph of this
Section 5 (or at such other place as shall be determined by agreement between
the Representatives and the Company) at 10:00 A.M., New York City time, on each
such Subsequent Delivery Date. On each such Subsequent Delivery Date, the
Company and the Selling Stockholders shall deliver or cause to be delivered the
certificates representing the Option Shares to be purchased on such Subsequent
Delivery Date to the Representatives for the account of each Underwriter against
payment to or upon the order of the Company and the Selling Stockholders of the
purchase price by wire transfer in immediately available funds. Time shall be of
the essence, and delivery at the time and place specified pursuant to this
Agreement is a further condition of the obligation of each Underwriter
hereunder. Upon delivery, the Option Shares shall be registered in such names
and in such denominations as the Representatives shall request in the aforesaid
written notice. For the purpose of expediting the checking and packaging of the
certificates for the Option Shares, the Company and the Selling Stockholders
shall make the certificates representing the Option Shares available for
inspection by the Representatives in New York, New York, not later than 2:00
P.M., New York City time, on the business day prior to each such Subsequent
Delivery Date.

     SECTION 6.   FURTHER AGREEMENTS OF THE COMPANY.  The Company agrees:

          (a)     To prepare the Prospectus in a form approved by the
Representatives and to file such Prospectus pursuant to Rule 424(b) under the
Securities Act not later than the Commission's close of business on the second
business day following the execution and delivery of this Agreement or, if
applicable, such earlier time as may be required by Rule 430A(a)(3) under the
Securities Act; to make no further amendment or any supplement to the
Registration Statement or to the Prospectus except as provided herein; to advise
the Representatives, promptly after it receives notice thereof, of the time when
any amendment to the Registration Statement has been filed or becomes effective
or any supplement to the Prospectus or any amended Prospectus has been filed and
to furnish the Representatives with copies thereof; to advise the
Representatives, promptly after it receives notice thereof, of the issuance by
the Commission of any stop order or of any order preventing or suspending the
use of any Preliminary Prospectus or the Prospectus, of the suspension of the
qualification of the Shares for offering or sale in any jurisdiction, of the
initiation or threatening of any proceeding for any such purpose, or of any
request by the Commission for the amending or supplementing of the Registration
Statement or the Prospectus or for additional information; and, in the event of
the issuance of any stop order or of any order preventing or suspending the use
of any Preliminary Prospectus or the Prospectus or suspending any such
qualification, to use promptly its best efforts to obtain its withdrawal;

                                       15
<Page>

          (b)     To furnish promptly to each of the Representatives and to
counsel for the Underwriters a signed copy of the Registration Statement as
originally filed with the Commission, and each amendment thereto filed with the
Commission, including all consents and exhibits filed therewith;

          (c)     To deliver promptly to the Representatives such number of the
following documents as the Representatives shall reasonably request: (i)
conformed copies of the Registration Statement as originally filed with the
Commission and each amendment thereto (in each case excluding exhibits) and (ii)
each Preliminary Prospectus, the Prospectus and any amended or supplemented
Prospectus; and, if the delivery of a prospectus is required at any time after
the Effective Time in connection with the offering or sale of the Shares and if
at such time any events shall have occurred as a result of which the Prospectus
as then amended or supplemented would include an untrue statement of a material
fact or omit to state any material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made
when such Prospectus is delivered, not misleading, or, if for any other reason
it shall be necessary to amend or supplement the Prospectus in order to comply
with the Securities Act, to notify the Representatives and, upon their request,
to prepare and file such amendment or supplement to the Prospectus and to
furnish without charge to each Underwriter and to any dealer in securities as
many copies as the Representatives may from time to time reasonably request of
an amended or supplemented Prospectus which will correct such statement or
omission or effect such compliance;

          (d)     To file promptly with the Commission any amendment to the
Registration Statement or the Prospectus or any supplement to the Prospectus
that may, in the reasonable judgment of the Company or the Representatives, be
required by the Securities Act or requested by the Commission;

          (e)     Prior to filing with the Commission any amendment to the
Registration Statement or supplement to the Prospectus or any Prospectus
pursuant to Rule 424 of the Rules and Regulations, to furnish a copy thereof to
the Representatives and counsel for the Underwriters to allow the
Representatives and their counsel a reasonable period of time to review and
comment thereon prior to filing and not to file any such amendment or supplement
to which the Representatives reasonably object;

          (f)     As soon as practicable after the Effective Date, to make
generally available to the Company's security holders and to deliver to the
Representatives an earnings statement of the Company and its subsidiaries (which
need not be audited) complying with Section 11(a) of the Securities Act and the
Rules and Regulations (including, at the option of the Company, Rule 158);

          (g)     For a period of five years following the Effective Date, to
furnish to the Representatives copies of all materials furnished by the Company
to its stockholders and all public reports and all reports and financial
statements furnished by the Company to the principal national securities
exchange or automatic quotation system upon which the Common Stock may be listed
or quoted pursuant to requirements of or

                                       16
<Page>

agreements with such exchange or automatic quotation system or to the Commission
pursuant to the Exchange Act or any rule or regulation of the Commission
thereunder, other than documents filed by the Company with the Commission and
available electronically through the Commission's EDGAR system (or any successor
system);

          (h)     Promptly from time to time to take such action as the
Representatives may reasonably request to qualify the Shares for offering and
sale under the securities laws of such jurisdictions as the Representatives may
request and to comply with such laws so as to permit the continuance of sales
and dealings therein in such jurisdictions for as long as may be necessary to
complete the distribution of the Shares; provided that in connection therewith
the Company shall not be required to qualify as a foreign corporation or to file
a general consent to service of process in any jurisdiction to which it is not
otherwise subject;

          (i)     For a period of 180 days from the date of the Prospectus (the
"LOCK-UP PERIOD"), not to, directly or indirectly: (i) offer for sale, sell,
pledge or otherwise dispose of (or enter into any transaction or device which is
designed to, or could be expected to, result in the disposition by any person at
any time in the future of) any shares of Common Stock or securities convertible
into or exchangeable for Common Stock (other than the Shares and shares issued
or issuable pursuant to any of the Plans or pursuant to currently outstanding
options, warrants or rights), or sell or grant options, rights or warrants with
respect to any shares of Common Stock or securities convertible into or
exchangeable for Common Stock (other than pursuant to any of the Plans); (ii)
enter into any swap or other derivatives transaction that transfers to another,
in whole or in part, any of the economic benefits or risks of ownership of such
shares of Common Stock (other than the Shares and shares issued or issuable
pursuant to any of the Plans or pursuant to currently outstanding options,
warrants or rights), whether any such transaction described in clause (i) or
(ii) above is to be settled by delivery of Common Stock or other securities, in
cash or otherwise; (iii) file or cause to be filed a registration statement with
respect to any shares of Common Stock or securities convertible, exercisable or
exchangeable into Common Stock or any other securities of the Company (other
than any registration statement or statements on Form S-8 relating to the
Plans); or (iv) publicly disclose the intention to do any of the acts prohibited
by the foregoing, in each case without the prior written consent of Lehman
Brothers Inc. on behalf of the Underwriters; PROVIDED, HOWEVER, that, if (1)
during the last 17 days of the Lock-Up Period, the Company issues an earnings
release or discloses, through a press release or the filing of a Current Report
on Form 8-K, the occurrence of a material event relating to the Company, or
Lehman Brothers, Inc., on behalf of the Underwriters, shall notify the Company
in writing that, in its reasonable judgment, a material event relating to the
Company has occurred, or (2) prior to the expiration of the Lock-Up Period, the
Company announces that it will issue an earnings release during the 16-day
period beginning on the last day of the Lock-Up Period, then the restrictions
described in this Section 6(i) shall continue to apply until the expiration of
the 18-day period beginning on the issuance of the earnings release or the
announcement of the material news or the occurrence of the material event,
unless Lehman Brothers Inc., on behalf of the

                                       17
<Page>

Underwriters, waives, in writing, such extension; PROVIDED FURTHER, HOWEVER,
that the restrictions described in this Section 6(i) shall automatically
terminate in the event that the Company issues any shares of Common Stock or
securities convertible into or exchangeable for Common Stock in an equity or
debt offering led or managed by any of the Representatives;

          (j)     To use its commercially reasonable efforts to cause each
stockholder, officer and director of the Company to furnish to the
Representatives, prior to the First Delivery Date, a letter or letters,
substantially in the form previously provided to counsel for the Company (the
"LOCK-UP LETTER"), pursuant to which each such person shall agree, subject to
certain exceptions in the Lock-up Letter, not to, directly or indirectly, (i)
offer for sale, sell, pledge or otherwise dispose of (or enter into any
transaction or device which is designed to, or could be expected to, result in
the disposition by any person at any time in the future of) any shares of Common
Stock or securities convertible into or exchangeable for Common Stock or (ii)
enter into any swap or other derivatives transaction that transfers to another,
in whole or in part, any of the economic benefits or risks of ownership of such
shares of Common Stock, whether any such transaction described in clause (i) or
(ii) above is to be settled by delivery of Common Stock or other securities, in
cash or otherwise, in each case for a period of 180 days from the date of the
Prospectus, without the prior written consent of Lehman Brothers Inc. on behalf
of the Underwriters;

          (k)     To apply to have the Shares listed for quotation on The Nasdaq
National Market, and to use its best efforts to complete that application,
subject only to official notice of issuance, prior to the First Delivery Date;

          (l)     To apply the net proceeds from the sale of the Shares being
sold by the Company as set forth in the Prospectus;

          (m)     To take such steps within its power as shall be necessary to
ensure that neither the Company nor any subsidiary shall become an "investment
company" or a company "controlled" by an "investment company" within the meaning
of the Investment Company Act of 1940, as amended.

          (n)     To enforce the terms of the Plan Lock-up with each of its
directors, officers and stockholders and each person who acquires shares of
Common Stock before the expiration of such Plan Lock-up pursuant to the exercise
of any option or right granted under the Plans, except as otherwise permitted
with the prior written consent of Lehman Brothers Inc. on behalf of the
Underwriters; and, unless otherwise instructed by Lehman Brothers Inc., to issue
and impose a stop-transfer instruction with the Company's transfer agent with
respect to the Plan Lock-up.

          The Company further acknowledges and agrees that the Underwriters'
research analysts and research departments are required to be independent from
their respective investment banking divisions and are subject to certain
regulations and internal policies, and that such Underwriters' research analysts
may hold and make statements or

                                       18
<Page>

investment recommendations and/or publish research reports with respect to the
Company and/or the offering of the Shares that differ from the views of the
Underwriters' respective investment bankers. The Company acknowledges that each
of the Underwriters is a full-service securities firm and, as such, from time to
time, subject to applicable securities laws, may effect transactions for its own
account or the account of its customers and hold long or short positions in debt
or equity securities of the Company.

     SECTION 7.   FURTHER AGREEMENTS OF THE SELLING STOCKHOLDERS. Each
Selling Stockholder agrees:

          (a)     To comply with the terms and conditions of the Lock-up Letter
between such Selling Stockholder and the Representatives;

          (b)     That the Shares to be sold by the Selling Stockholder
hereunder which are represented by the certificates held in custody for the
Selling Stockholder are subject to the interest of the Underwriters and the
other Selling Stockholders hereunder, that the arrangements made by the Selling
Stockholder for such custody are to that extent irrevocable, and that the
obligations of the Selling Stockholder hereunder shall not be terminated by any
act of the Selling Stockholder, by operation of law, by the death or incapacity
of any individual Selling Stockholder or, in the case of a trust, by the death
or incapacity of any executor or trustee or the termination of such trust, or
the occurrence of any other event; and

          (c)     To deliver to the Representatives prior to the First Delivery
Date, a properly completed and executed United States Treasury Department Form
W-8 (if the Selling Stockholder is a non-United States person) or Form W-9 (if
the Selling Stockholder is a United States person).

     SECTION 8.   EXPENSES. Except as otherwise agreed to in writing by the
Company and Lehman Brothers Inc. on behalf of the Representatives, the Company
agrees to pay all costs and expenses incident to the performance of the
obligations of the Company under this Agreement and in connection with the
Transactions, including: (a) the costs incident to the authorization, issuance,
sale and delivery of the Shares being sold by it hereunder and any taxes payable
in that connection; (b) the costs incident to the preparation, printing and
filing under the Securities Act of the Registration Statement and any amendments
and exhibits thereto; (c) the costs of distributing the Registration Statement
as originally filed and each amendment thereto and any post-effective amendments
thereof (including, in each case, exhibits), any Preliminary Prospectus, the
Prospectus and any amendment or supplement to the Prospectus, all as provided in
this Agreement; (d) the costs of producing and distributing this Agreement, the
Agreement Between U.S. Underwriters and International Managers, any Supplemental
Agreement Among U.S. Underwriters and any other related documents in connection
with the offering, purchase, sale and delivery of the Shares; (e) the fees and
expenses of the Custodian and any attorney-in-fact and the costs of delivering
and distributing the Custody Agreements and the Powers of Attorney; (f) the
filing fees incident to securing the review by the NASD of the terms of sale of
the Shares (including related fees and

                                       19
<Page>

expenses of counsel to the Underwriters incurred in connection with such review,
not in excess, in the aggregate, of $10,000); (g) any applicable listing,
quotation or other fees; (h) the fees and expenses (not in excess, in the
aggregate, of $10,000) of qualifying the Shares under the securities laws of the
several jurisdictions as provided in Section 6(h) and of preparing, printing and
distributing a Blue Sky Memorandum (including related fees and expenses of
counsel to the Underwriters); (i) the costs and expenses of the Company relating
to investor presentations on any "road show" undertaken in connection with the
marketing of the offering of the Shares, including, without limitation, expenses
associated with the production of road show slides and graphics, fees and
expenses of any consultants engaged in connection with the road show
presentations with the prior approval of the Company, travel and lodging
expenses of the representatives and officers of the Company and any such
consultants, and the cost of any aircraft chartered in connection with the road
show; and (j) all other costs and expenses incident to the performance of the
obligations of the Company under this Agreement; PROVIDED, HOWEVER, that, except
as provided in this Section 8 and in Section 13, the Underwriters shall pay
their own costs and expenses, including the costs and expenses of their counsel,
any transfer taxes on the Shares that they may sell and the expenses of
advertising any offering of the Shares made by the Underwriters. Except as
otherwise agreed to by the Company and the Selling Stockholders, the fees and
expenses of the Selling Stockholders shall be paid in the manner set forth in
that certain Registration Rights Agreement made as of November 20, 2000 by and
among the Company and certain of its stockholders.

     SECTION 9.   CONDITIONS OF UNDERWRITERS' OBLIGATIONS. The respective
obligations of the Underwriters hereunder are subject to the accuracy, when made
and on each Delivery Date, of the representations and warranties of the Company
and the Selling Stockholders contained herein, to the performance by the Company
and the Selling Stockholders of their respective obligations hereunder, and to
each of the following additional terms and conditions:

          (a)     The Prospectus shall have been timely filed with the
Commission in accordance with Section 6(a); no stop order suspending the
effectiveness of the Registration Statement or any part thereof shall have been
issued and no proceeding for that purpose shall have been initiated or
threatened by the Commission; and any request of the Commission for inclusion of
additional information in the Registration Statement or the Prospectus or
otherwise shall have been complied with.

          (b)     No Underwriter shall have discovered and disclosed to the
Company on or prior to such Delivery Date that the Registration Statement or the
Prospectus or any amendment or supplement thereto contains an untrue statement
of a fact that, in the opinion of such Underwriter or Wilson Sonsini Goodrich &
Rosati, Professional Corporation, counsel for the Underwriters, is material or
omits to state a fact that, in the opinion of such Underwriter or such counsel,
is material or is required to be stated therein or is necessary to make the
statements therein not misleading.

          (c)     All corporate proceedings and other legal matters incident to
the authorization, form and validity of this Agreement, the Custody Agreements,
the Powers

                                       20
<Page>

of Attorney, the Shares, the Registration Statement and the Prospectus, and all
other legal matters relating to this Agreement and the Transactions shall be
reasonably satisfactory in all material respects to counsel for the
Underwriters, and the Company and the Selling Stockholders shall have furnished
to such counsel all documents and information that they may reasonably request
to enable them to pass upon such matters.

          (d)     Foley Hoag LLP shall have furnished to the Representatives its
written opinion, as counsel to the Company, addressed to the Underwriters and
dated such Delivery Date, in form and substance satisfactory to the
Representatives, to the effect that:

                  (i)    The Company has been duly incorporated and is validly
          existing as a corporation in good standing under the laws of Delaware,
          is duly registered to do business as a foreign corporation in the
          Commonwealth of Massachusetts and has all corporate power and
          authority necessary to own or hold its properties and conduct its
          businesses as described in the Prospectus;

                  (ii)   The Company has an authorized capitalization as set
          forth in the Prospectus under the caption "Description of Capital
          Stock - General Matters," and all of the issued and outstanding shares
          of capital stock of the Company (excluding the Shares being delivered
          by the Company on such Delivery Date to the Underwriters hereunder)
          have been duly and validly authorized and issued, are fully paid and
          non-assessable and conform to the description thereof contained in the
          Prospectus;

                  (iii)  The Shares being delivered by the Company on such
          Delivery Date to the Underwriters hereunder have been duly and validly
          authorized and, when issued and delivered against payment therefor in
          accordance with the terms hereof, will be duly and validly issued,
          fully paid and non-assessable;

                  (iv)   Except as described in the Prospectus and except for
          such rights as have been waived, there are no preemptive or other
          rights to subscribe for or to purchase, nor any restriction upon the
          voting or transfer of, any of the Shares pursuant to the Company's
          certificate of incorporation or bylaws or any agreement or other
          instrument known to such counsel and to which the Company is a party;

                  (v)    To such counsel's knowledge and except for the matters
          described in the Prospectus, there are no legal or governmental
          proceedings pending or threatened to which the Company is a party or
          of which any property or assets of the Company is the subject which,
          if determined adversely to the Company, would be reasonably likely to
          have a Material Adverse Effect;

                                       21
<Page>

                  (vi)   The Registration Statement and any Rule 462(b)
          Registration Statement were declared effective under the Securities
          Act as of the date or dates specified in such opinion, the Prospectus
          was filed with the Commission pursuant to the subparagraph of Rule
          424(b) of the Rules and Regulations specified in such opinion on the
          date specified therein, and, to such counsel's knowledge, no stop
          order suspending the effectiveness of the Registration Statement has
          been issued and no proceeding for that purpose is pending or
          threatened by the Commission;

                  (vii)  The Registration Statement, as of its effective date,
          and the Prospectus, as of its filing date, and any amendments or
          supplements thereto made by the Company prior to such Delivery Date,
          as of their respective effective or filing dates (except in each case
          for the financial statements, the notes thereto, the financial
          schedules and the financial, accounting and statistical data and
          information derived therefrom, as to which such counsel need express
          no opinion) complied as to form in all material respects with the
          requirements of the Securities Act and the Rules and Regulations;

                  (viii) The statements contained in the Prospectus under the
          captions "Risk Factors - If we fail to comply with government
          contracting regulations, we could suffer a loss of revenue or incur
          price adjustments or other penalties", "Risk Factors - If we fail to
          comply with environmental regulations we could be subject to
          substantial fines or be required to suspend production, alter
          manufacturing processes or cease operations," the first three
          sentences of the third paragraph of Management's Discussion and
          Analysis of Financial Condition and Results of Operations - Recent
          Accounting Pronouncements", "Business - Government Regulation - Export
          regulations", "Business - Government Regulation - Government
          contracting regulations", "Management - Liability Limitations and
          Indemnification", "Description of Capital Stock" and the statements
          contained in Item 14 of the Registration Statement, insofar as they
          describe federal or state statutes, rules and regulations, constitute
          a fair summary thereof in all material respects, and the opinion of
          such counsel filed as Exhibit 5.1 to the Registration Statement is
          confirmed, and the Underwriters may rely upon such opinion as if it
          were addressed to them;

                  (ix)   To such counsel's knowledge, there are no contracts or
          other documents which are required to be described in the Prospectus
          or filed as exhibits to the Registration Statement by the Securities
          Act or by the Rules and Regulations that have not been so described or
          filed;

                  (x)    This Agreement has been duly authorized, executed and
          delivered by the Company;

                                       22
<Page>

                  (xi)   The issuance and sale of the Shares being delivered on
          such Delivery Date by the Company pursuant to this Agreement, the
          execution, delivery and performance by the Company of its obligations
          under this Agreement and the consummation by the Company of the
          transactions contemplated hereby will not result in a breach or
          violation of any of the terms or provisions of, or constitute a
          default under, any indenture, mortgage, deed of trust, loan agreement
          or other agreement or instrument filed as an exhibit to the
          Registration Statement, nor will such actions result in any violation
          of the provisions of the charter or bylaws of the Company or any
          material violation of any statute, order, rule or regulation known to
          such counsel of any federal or Massachusetts court or governmental
          agency or body having jurisdiction over the Company or any of its
          properties or assets; and, except for the registration of the Shares
          under the Securities Act and such consents, approvals, authorizations,
          orders, filings, registrations or qualifications as may be required
          under the Exchange Act, applicable state or foreign securities laws in
          connection with the purchase and distribution of the Shares by the
          Underwriters, the rules of the Nasdaq Stock Market, Inc. and the rules
          of the NASD, no consent, approval, authorization or order of, or
          filing or registration with, any such federal or Massachusetts court
          or governmental agency or body is required for the execution, delivery
          and performance by the Company of its obligations under this Agreement
          and the consummation by the Company of the transactions contemplated
          hereby, except for such consents, approvals, authorizations, orders,
          filings, registrations or qualifications as have been obtained or
          made;

                  (xii)  Except for the statements contained in the Prospectus
          under the heading "Description of Capital Stock--Registration Rights,"
          to such counsel's knowledge, there are no contracts or agreements
          between the Company and any person granting such person the right to
          require the Company to file a registration statement under the
          Securities Act with respect to any securities of the Company owned or
          to be owned by such person or to require the Company to include such
          securities in the securities registered pursuant to the Registration
          Statement or in any securities being registered pursuant to any other
          registration statement filed by the Company under the Securities Act;

                  (xiii) The Company is not, and after giving effect to the
          Transactions and the application of the net proceeds from the Shares
          being sold by the Company as described in the Prospectus, will not be,
          an "investment company" as defined in the Investment Company Act of
          1940, as amended.

                  (xiv)  The cash dividend in the aggregate amount of
          approximately $34.2 million payable immediately prior to the First
          Delivery Date (as defined below) (A) has been duly and validly
          authorized

                                       23
<Page>

          by all necessary corporate action on the part of the Company and its
          stockholders, (B) has not resulted and will not result in a breach or
          violation of any of the terms or provisions of any agreement, license
          or instrument to which the Company is a party or by which the Company
          is bound or to which any of the property or assets of the Company is
          subject and that is filed as an exhibit to the Registration Statement,
          except for such breaches and violations as have been validly waived,
          (C) has not resulted and will not result in any violation of the
          provisions of the charter or bylaws of the Company, (D) to such
          counsel's knowledge has not resulted and will not result in any
          violation of any statute or any order, rule or regulation of any court
          or governmental agency or body having jurisdiction over the Company or
          any of its properties or assets. The Prospectus contains a fair and
          accurate summary in all material respects of such cash dividend under
          the heading "Dividend Policy."

In rendering such opinion, such counsel may state that its opinion is limited to
matters governed by the Federal laws of the United States of America, the laws
of the Commonwealth of Massachusetts and the General Corporation Law of the
State of Delaware, that it is subject to such assumptions, limitations and
qualifications as are stated therein, and that, insofar as such opinion involves
factual matters, it has relied upon certificates of officers of the Company and
such other persons as it shall deem appropriate. Such opinion shall also be to
the effect that (i) such counsel has acted as counsel to the Company in
connection with the preparation of the Registration Statement and (ii) based on
the foregoing and such matters as such counsel shall describe therein, no facts
have come to the attention of such counsel that lead it to believe that the
Registration Statement (except in each case for the financial statements, the
notes thereto, the financial schedules and the financial, accounting and
statistical data and information derived therefrom, as to which such counsel
need express no opinion) as of the Effective Date, contained any untrue
statement of a material fact or omitted to state a material fact required to be
stated therein or necessary to make the statements therein not misleading, or
that the Prospectus (except as stated above) contains any untrue statement of a
material fact or omits to state a material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were
made, not misleading. The foregoing opinion and statement may be qualified by a
statement to the effect that (other than as set forth in clause (viii and xiv)
above) such counsel does not assume any responsibility for the accuracy,
completeness or fairness of the statements contained in the Registration
Statement or the Prospectus.

          (e)     The Representatives shall have received from Iandiorio &
Teska, intellectual property counsel for the Company, such opinion, dated such
Delivery Date, with respect to the matters set forth in EXHIBIT A hereto.

          (f)     The Representatives shall have received from Wilson Sonsini
Goodrich & Rosati, Professional Corporation, counsel for the Underwriters, such
opinion, dated such Delivery Date, with respect to the issuance and sale of the
Shares, the Registration Statement, the Prospectus and other related matters as
the Representatives

                                       24
<Page>

may reasonably require, and the Company shall have furnished to such counsel
such documents as they reasonably request for the purpose of enabling them to
pass upon such matters.

          (g)     Counsel to each of the Selling Stockholders shall have
furnished to the Representatives its written opinion, as counsel to such Selling
Stockholder, addressed to the Underwriters and dated such Delivery Date, in the
form attached hereto as EXHIBIT B.

          (h)     At the time of execution of this Agreement, the
Representatives shall have received from PricewaterhouseCoopers LLP a letter, in
form and substance satisfactory to the Representatives, addressed to the
Underwriters and dated the date hereof (i) confirming that they are independent
public accountants within the meaning of the Securities Act and the Rules and
Regulations and the rules and regulations of the Public Company Accounting
Oversight Board (United States) and are in compliance with the applicable
requirements relating to the qualification of accountants under Rule 2-01 of
Regulation S-X of the Rules and Regulations and (ii) stating, as of the date
hereof (or, with respect to matters involving changes or developments since the
respective dates as of which specified financial information is given in the
Prospectus, as of a date not more than five days prior to the date hereof), the
conclusions and findings of such firm with respect to the financial information
and other matters ordinarily covered by accountants' "comfort letters" to
underwriters in connection with registered public offerings.

          (i)     With respect to the letter of PricewaterhouseCoopers LLP
referred to in the preceding paragraph and delivered to the Representatives
concurrently with the execution of this Agreement (the "INITIAL LETTER"),
PricewaterhouseCoopers LLP shall have delivered to the Representatives a letter
(the "BRING-DOWN LETTER") of such accountants, addressed to the Underwriters and
dated such Delivery Date (i) confirming that they are independent public
accountants within the meaning of the Securities Act and the Rules and
Regulations and the rules and regulations of the Public Company Accounting
Oversight Board (United States) and are in compliance with the applicable
requirements relating to the qualification of accountants under Rule 2-01 of
Regulation S-X of the Rules and Regulations, (ii) stating, as of the date of the
Bring-down Letter (or, with respect to matters involving changes or developments
since the respective dates as of which specified financial information is given
in the Prospectus, as of a date not more than five days prior to the date of the
Bring-down Letter), the conclusions and findings of such firm with respect to
the financial information and other matters covered by the Initial Letter and
(iii) confirming in all material respects the conclusions and findings set forth
in the Initial Letter.

          (j)     The Company shall have furnished to the Representatives a
certificate, dated such Delivery Date, executed on behalf of the Company by its
Chairman of the Board, its President or a Vice President and its Chief Financial
Officer stating severally that:

                                       25
<Page>

                  (i)    The representations, warranties and agreements of the
          Company in Section 1 are true and correct as of such Delivery Date;
          the Company has complied with all its agreements contained herein; and
          the conditions set forth in Sections 9(a) and 9(l) have been
          fulfilled;

                  (ii)   The signatory has carefully examined the Registration
          Statement and the Prospectus and, in his opinion (A) the Registration
          Statement and any amendment thereto did not, as of the applicable
          effective date, contain an untrue statement of a material fact or omit
          to state a material fact required to be stated therein or necessary to
          make the statements therein not misleading, and the Prospectus and any
          amendment or supplement thereto did not, as of the applicable filing
          date, and does not, as of the Delivery Date, contain an untrue
          statement of a material fact or omit to state a material fact required
          to be stated therein or necessary to make the statements therein, in
          the light of the circumstances under which they were made, not
          misleading, and (B) since the Effective Date, no event has occurred
          that should have been set forth in a supplement or amendment to the
          Registration Statement or the Prospectus that has not been so set
          forth; and

                  (iii)  To the knowledge of the signatory, the issuance and
          sale of the Shares by the Company hereunder has not been enjoined
          (temporarily or permanently) by any court or governmental body or
          agency.

          (k)     Each Selling Stockholder (or one or more attorneys in fact on
behalf of the Selling Stockholders) shall have furnished to the Representatives
on such Delivery Date a certificate, dated such Delivery Date, signed by, or on
behalf of, the Selling Stockholder (or one or more attorneys in fact) stating
that the representations, warranties and agreements of the Selling Stockholder
contained herein are true and correct as of such Delivery Date and that the
Selling Stockholder has complied with all agreements contained herein to be
performed by the Selling Stockholder at or prior to such Delivery Date.

          (l)     Neither the Company nor any of its subsidiaries shall have
sustained since the date of the latest audited financial statements included in
the Prospectus (i) any loss or interference with its business from fire,
explosion, flood or other calamity, whether or not covered by insurance, or from
any labor dispute or court or governmental action, order or decree, otherwise
than as set forth or contemplated in the Prospectus or (ii) since such date,
there shall not have been any change in the capital stock or long-term debt of
the Company or any of its subsidiaries or any change, or any development
involving a prospective change, in or affecting the general affairs, management,
financial position, stockholders' equity or results of operations of the Company
and its subsidiaries, otherwise than as set forth or contemplated in the
Prospectus, the effect of which, in any such case described in clause (i) or
(ii), is, in the judgment of the Representatives, so material and adverse as to
make it impracticable or inadvisable to proceed with the public offering or the
delivery of the Shares being

                                       26
<Page>

delivered on such Delivery Date on the terms and in the manner contemplated
herein and in the Prospectus.

          (m)     Subsequent to the execution and delivery of this Agreement
there shall not have occurred any of the following: (i) trading in securities
generally on the New York Stock Exchange or the American Stock Exchange or in
the over-the-counter market, or trading in any securities of the Company on any
exchange or in the over-the-counter market, shall have been suspended or the
settlement of such trading generally shall have been materially disrupted or
minimum prices shall have been established on any such exchange or such market
by the Commission, by such exchange or by any other regulatory body or
governmental authority having jurisdiction, (ii) a banking moratorium shall have
been declared by Federal or state authorities, (iii) the United States shall
have become engaged in hostilities, there shall have been an escalation in
hostilities involving the United States or there shall have been a declaration
of a national emergency or war by the United States or (iv) there shall have
occurred such a material adverse change in general economic, political or
financial conditions (or the effect of international conditions on the financial
markets in the United States shall be such) or there shall have occurred any
other calamity or crisis, including without limitation as a result of terrorist
activities after the date hereof, as to make it, in the judgment of the
Representatives, impracticable or inadvisable to proceed with the offering or
delivery of the Shares being delivered on such Delivery Date on the terms and in
the manner contemplated in the Prospectus.

          (n)     The Nasdaq Stock Market, Inc. shall have approved the Shares
for listing on the Nasdaq National Market, subject only to official notice of
issuance.

All opinions, letters, evidence and certificates mentioned above or elsewhere in
this Agreement shall be deemed to be in compliance with the provisions hereof
only if they are in form and substance reasonably satisfactory to counsel for
the Underwriters.

     SECTION 10.  INDEMNIFICATION AND CONTRIBUTION.

          (a)     The Company shall indemnify and hold harmless each
Underwriter, its directors, officers, employees and agents and each person, if
any, who controls any Underwriter within the meaning of Section 15 of the
Securities Act, from and against any loss, claim, damage or liability, joint or
several, or any action in respect thereof, to which that Underwriter, director,
officer, employee, agent or controlling person may become subject, under the
Securities Act or otherwise, insofar as such loss, claim, damage, liability or
action arises out of, or is based upon, (i) any untrue statement or alleged
untrue statement of a material fact contained (A) in any Preliminary Prospectus,
the Registration Statement or the Prospectus or in any amendment or supplement
thereto, or (B) in any materials or information provided to investors by, or
with the written approval of, the Company in connection with the marketing of
the offering of the Shares, including any road show or investor presentations
made to investors by the Company (whether in person or electronically)
("MARKETING MATERIALS"), (ii) the omission or alleged omission to state in any
Preliminary Prospectus,

                                       27
<Page>

the Registration Statement or the Prospectus, or in any amendment or supplement
thereto, or in any Marketing Materials, any material fact required to be stated
therein or necessary to make the statements therein not misleading, or (iii) any
act or failure to act or any alleged act or failure to act by any Underwriter in
connection with, or relating in any manner to, the Shares or the offering
contemplated hereby, and that is included as part of or referred to in any loss,
claim, damage, liability or action arising out of or based upon matters covered
by clause (i) or (ii) above (PROVIDED, HOWEVER, that the Company shall not be
liable under this clause (iii) to the extent that it is determined in a final
judgment by a court of competent jurisdiction that such loss, claim, damage,
liability or action resulted directly from any such acts or failures to act
undertaken or omitted to be taken by any Underwriter through its gross
negligence or willful misconduct), and shall reimburse each Underwriter and each
such director, officer, employee, agent or controlling person promptly upon
demand for any legal or other expenses reasonably incurred by that Underwriter,
director, officer, employee, agent or controlling person in connection with
investigating or defending or preparing to defend against any such loss, claim,
damage, liability or action as such expenses are incurred; PROVIDED, HOWEVER,
that the Company shall not be liable in any such case to the extent that any
such loss, claim, damage, liability or action arises out of, or is based upon,
any untrue statement or alleged untrue statement or omission or alleged omission
made in any Preliminary Prospectus, the Registration Statement or the
Prospectus, or in any such amendment or supplement, in reliance upon and in
conformity with written information concerning such Underwriter furnished to the
Company through the Representatives by or on behalf of any Underwriter
specifically for inclusion therein, which information consists solely of the
information specified in Section 10(f); AND PROVIDED, FURTHER, that the Company
shall not be liable in any such case to the extent that any such loss, claim,
damage, liability or action arises out of, or is based upon, any untrue
statement or alleged untrue statement or omission or alleged omission made in
any Preliminary Prospectus or any Marketing Materials if (x) the Company shall
have furnished copies of the Prospectus to the several Underwriters in the
requisite quantity and sufficiently in advance of confirmation of sale to permit
proper delivery of the Prospectus to such person at or prior to the confirmation
of sale, and the person alleging such loss, claim, damage, liability or action
purchased Shares from the Underwriters but was not sent or did not receive a
copy of the Prospectus (as then amended or supplemented); (y) such misstatement
or omission or alleged misstatement or omission was cured in the Prospectus; and
(z) the timely delivery of the Prospectus to such person would have constituted
a complete defense to the losses, claims, damages, liabilities and judgments
asserted by such person. The foregoing indemnity agreement is in addition to any
liability that the Company may otherwise have to any Underwriter or to any
director, officer, employee, agent or controlling person of that Underwriter.

          (b)     Each Selling Stockholder, severally and not jointly, shall
indemnify and hold harmless each Underwriter, its directors, officers, employees
and agents, and each person, if any, who controls any Underwriter within the
meaning of Section 15 of the Securities Act, from and against any loss, claim,
damage or liability, joint or several, or any action in respect thereof
(including, but not limited to, any loss, claim, damage, liability or

                                       28
<Page>

action relating to purchases and sales of Shares), to which that Underwriter,
director, officer, employee, agent or controlling person may become subject,
under the Securities Act or otherwise, insofar as such loss, claim, damage,
liability or action arises out of, or is based upon, (i) any untrue statement or
alleged untrue statement of a material fact contained in any Preliminary
Prospectus, the Registration Statement or the Prospectus or in any amendment or
supplement thereto, or (ii) the omission or alleged omission to state in any
Preliminary Prospectus, Registration Statement or the Prospectus, or in any
amendment or supplement thereto, any material fact required to be stated therein
or necessary to make the statements therein not misleading, but in each case
only to the extent that the untrue statement or alleged untrue statement or
omission or alleged omission was made in reliance upon and in conformity with
written information concerning such Selling Stockholder furnished to the Company
by such Selling Stockholder specifically for inclusion therein, and shall
reimburse each Underwriter, its directors, officers, employees and agents and
each such controlling person for any legal or other expenses reasonably incurred
by that Underwriter, its directors, officers, employees, agents or controlling
person in connection with investigating or defending or preparing to defend
against any such loss, claim, damage, liability or action as such expenses are
incurred; PROVIDED, HOWEVER, that the aggregate liability of any Selling
Stockholder to the Underwriters and their directors, officers, employees, agents
and controlling persons shall not exceed the aggregate purchase price, less
underwriting discounts and commissions, received by such Selling Stockholder
from the sale of Shares by it under this Agreement; PROVIDED, FURTHER, that such
Selling Stockholder shall not be liable to any Underwriter or any of its
directors, officers, employees, agents or controlling persons in any such case
to the extent that any such loss, claim, damage, liability or action arises out
of, or is based upon, any untrue statement or alleged untrue statement or
omission or alleged omission made in any Preliminary Prospectus or any Marketing
Materials if (x) the Company shall have furnished copies of the Prospectus to
the several Underwriters in the requisite quantity and sufficiently in advance
of confirmation of sale to permit proper delivery of the Prospectus to such
person at or prior to the confirmation of sale, and the person alleging such
loss, claim, damage, liability or action purchased Shares from the Underwriters
but was not sent or did not receive a copy of the Prospectus (as then amended or
supplemented); (y) such misstatement or omission or alleged misstatement or
omission was cured in the Prospectus; and (z) the timely delivery of the
Prospectus to such person would have constituted a complete defense to the
losses, claims, damages, liabilities and judgments asserted by such person; AND
PROVIDED, FURTHER, that such Selling Stockholder shall not be liable to any
Underwriter or any of its directors, officers, employees, agents or controlling
persons in any such case to the extent that any such loss, claim, damage,
liability or action arises out of, or is based upon, any untrue statement or
alleged untrue statement or omission or alleged omission made in any Preliminary
Prospectus, the Registration Statement or the Prospectus or in any such
amendment or supplement, in reliance upon and in conformity with written
information concerning such Underwriter furnished to the Company through the
Representatives by or on behalf of any Underwriter specifically for inclusion
therein, which information consists solely of the information specified in
Section 10(f). The foregoing indemnity agreement is in addition to any liability
that the Selling Stockholders

                                       29
<Page>

may otherwise have to any Underwriter or any director, officer, employee, agent
or controlling person of that Underwriter.

          (c)     Each Underwriter, severally and not jointly, shall indemnify
and hold harmless the Company, its officers who have signed the Registration
Statement, each of its directors, each Selling Stockholder, and each person, if
any, who controls the Company or any Selling Stockholder within the meaning of
Section 15 of the Securities Act, from and against any loss, claim, damage or
liability, joint or several, or any action in respect thereof, to which the
Company or any such director, officer, Selling Stockholder or controlling person
may become subject, under the Securities Act or otherwise, insofar as such loss,
claim, damage, liability or action arises out of, or is based upon, (i) any
untrue statement or alleged untrue statement of a material fact contained in any
Preliminary Prospectus, the Registration Statement or the Prospectus or in any
amendment or supplement thereto, or (ii) the omission or alleged omission to
state in any Preliminary Prospectus, the Registration Statement or the
Prospectus, or in any amendment or supplement thereto, any material fact
required to be stated therein or necessary to make the statements therein not
misleading, but in each case only to the extent that the untrue statement or
alleged untrue statement or omission or alleged omission was made in reliance
upon and in conformity with written information concerning such Underwriter
furnished to the Company through the Representatives by or on behalf of that
Underwriter specifically for inclusion therein, which information consists
solely of the information specified in Section 10(f), and shall reimburse the
Company and any such director, officer, Selling Stockholder or controlling
person for any legal or other expenses reasonably incurred by the Company or any
such director, officer, Selling Stockholder or controlling person in connection
with investigating or defending or preparing to defend against any such loss,
claim, damage, liability or action as such expenses are incurred. The foregoing
indemnity agreement is in addition to any liability that any Underwriter may
otherwise have to the Company or any such director, officer, Selling
Stockholder, employee or controlling person.

          (d)     Promptly after receipt by an indemnified party under this
Section 10 of notice of any claim or the commencement of any action, the
indemnified party shall, if a claim in respect thereof is to be made against the
indemnifying party under this Section 10, notify the indemnifying party in
writing of the claim or the commencement of that action; PROVIDED, HOWEVER, that
the failure to notify the indemnifying party shall not relieve it from any
liability which it may have under this Section 10 except to the extent it has
been materially prejudiced by such failure and, PROVIDED FURTHER, HOWEVER, that
the failure to notify the indemnifying party shall not relieve it from any
liability which it may have to an indemnified party otherwise than under this
Section 10. If any such claim or action shall be brought against an indemnified
party, and it shall notify the indemnifying party thereof, the indemnifying
party shall be entitled to participate therein and, to the extent that it
wishes, jointly with any other similarly notified indemnifying party, to assume
the defense thereof with counsel reasonably satisfactory to the indemnified
party. After notice from the indemnifying party to the indemnified party of its
election to assume the defense of such claim or action, the indemnifying party
shall not be liable to

                                       30
<Page>

the indemnified party under this Section 10 for any legal or other expenses
subsequently incurred by the indemnified party in connection with the defense
thereof other than reasonable costs of investigation; PROVIDED, HOWEVER, that
the indemnified party shall have the right to employ counsel to represent
jointly the indemnified party and any other indemnified party and their
respective directors, officers, employees, agents and controlling persons who
may be subject to liability arising out of any claim in respect of which
indemnity may be sought by the indemnified party against the indemnifying party
or parties under this Section 10 if, in the reasonable judgment of the
indemnified party, it is advisable for the indemnified party and any other
indemnified party (including their respective directors, officers, employees,
agents and controlling persons) to be jointly represented by separate counsel,
and in that event the reasonable fees and expenses of such separate counsel
shall be paid by the indemnifying party. No indemnifying party shall (i) without
the prior written consent of the indemnified parties (which consent shall not be
unreasonably withheld), settle or compromise or consent to the entry of any
judgment with respect to any pending or threatened claim, action, suit or
proceeding in respect of which indemnification or contribution may be sought
hereunder (whether or not the indemnified parties are actual or potential
parties to such claim or action) unless such settlement, compromise or consent
includes an unconditional release of each indemnified party from all liability
arising out of such claim, action, suit or proceeding and does not include any
findings of fact or admissions of fault or culpability as to the indemnified
party, or (ii) be liable for any settlement of any such action effected without
its written consent (which consent shall not be unreasonably withheld), but if
settled with the consent of the indemnifying party or if there be a final
judgment of the plaintiff in any such action, the indemnifying party agrees to
indemnify and hold harmless any indemnified party from and against any loss or
liability by reason of such settlement or judgment (subject, in the case of
judgments, to the term, conditions and limitations of this Section 10).

          (e)     If the indemnification provided for in this Section 10 shall
for any reason be unavailable to or insufficient to hold harmless an indemnified
party under Section 10(a), 10(b) or 10(c) in respect of any loss, claim, damage
or liability, or any action in respect thereof, referred to therein, then each
indemnifying party shall, in lieu of indemnifying such indemnified party,
contribute to the amount paid or payable by such indemnified party as a result
of such loss, claim, damage or liability, or action in respect thereof, (i) in
such proportion as shall be appropriate to reflect the relative benefits
received by the Company and the Selling Stockholders on the one hand and the
Underwriters on the other from the offering of the Shares or (ii) if the
allocation provided by clause (i) above is not permitted by applicable law, in
such proportion as is appropriate to reflect not only the relative benefits
referred to in clause (i) above but also the relative fault of the Company and
the Selling Stockholders on the one hand and the Underwriters on the other with
respect to the statements or omissions which resulted in such loss, claim,
damage or liability, or action in respect thereof, as well as any other relevant
equitable considerations. The relative benefits received by the Company and the
Selling Stockholders on the one hand and the Underwriters on the other with
respect to such offering shall be deemed to be in the same proportion as the
total net proceeds from

                                       31
<Page>

the offering of the Shares purchased under this Agreement (before deducting
expenses) received by the Company and the Selling Stockholders, on the one hand,
and the total underwriting discounts and commissions received by the
Underwriters with respect to the Shares purchased under this Agreement, on the
other hand, bear to the total gross proceeds from the offering of the Shares
under this Agreement, in each case as set forth in the table on the cover page
of the Prospectus. The relative fault shall be determined by reference to
whether the untrue or alleged untrue statement of a material fact or omission or
alleged omission to state a material fact relates to information supplied by the
Company, the Selling Stockholders or the Underwriters, the intent of the parties
and their relative knowledge, access to information and opportunity to correct
or prevent such statement or omission. The Company, the Selling Stockholders and
the Underwriters agree that it would not be just and equitable if contributions
pursuant to this Section 10(e) were to be determined by pro rata allocation
(even if the Underwriters were treated as one entity for such purpose) or by any
other method of allocation which does not take into account the equitable
considerations referred to herein. The amount paid or payable by an indemnified
party as a result of the loss, claim, damage or liability, or action in respect
thereof, referred to above in this Section 10 shall be deemed to include, for
purposes of this Section 10(e), any legal or other expenses reasonably incurred
by such indemnified party in connection with investigating or defending or
preparing to defend any such action or claim. Notwithstanding the provisions of
this Section 10(e), (i) no Underwriter shall be required to contribute any
amount in excess of the amount by which the total price at which the Shares
underwritten by it and distributed to the public was offered to the public
exceeds the amount of any damages which such Underwriter has otherwise paid or
become liable to pay by reason of any untrue or alleged untrue statement or
omission or alleged omission and (ii) no Selling Stockholder shall be required
to contribute any amount in excess of the amount by which the aggregate purchase
price, less underwriting discounts and commissions, received by such Selling
Stockholder from the sale of Shares exceeds the amount of any damages which such
Selling Stockholder has otherwise paid or become liable to pay by reason of any
untrue or alleged untrue statement or omission or alleged omission. No person
guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of
the Securities Act) shall be entitled to contribution from any person who was
not guilty of such fraudulent misrepresentation. The Underwriters' obligations
to contribute as provided in this Section 10(e) are several in proportion to
their respective underwriting obligations and not joint. The Selling
Stockholders' obligations to contribute as provided in this Section 10(e) are
several in proportion to the number of Shares to be sold by each of them
hereunder and not joint.

          (f)     The Underwriters severally confirm and the Company and the
Selling Stockholders acknowledge that (i) the statements with respect to the
public offering of the Shares by the Underwriters set forth on the cover page of
the Prospectus, and (ii) the second paragraph in the subsection entitled
"Commissions and Expenses," the third sentence in the subsection entitled
"Offering Price Determination," the first, second and fourth paragraphs under
the subsection entitled "Stabilization, Short Positions and Penalty Bids"
(except as it relates to statements or actions of the Company), the

                                       32
<Page>

subsection entitled "Electronic Distribution" (except as it relates to
statements or actions of the Company), and the subsection entitled
"Discretionary Sales," in each case under the caption "Underwriting" in, the
Prospectus are correct and constitute the only information concerning such
Underwriters furnished in writing to the Company by or on behalf of the
Underwriters specifically for inclusion in the Registration Statement and the
Prospectus.

     SECTION 11.  DEFAULTING UNDERWRITERS.

If, on any Delivery Date, any Underwriter defaults in the performance of its
obligations under this Agreement, the remaining non-defaulting Underwriters
shall be obligated to purchase the Shares which the defaulting Underwriter
agreed but failed to purchase on such Delivery Date in the respective
proportions which the number of shares of the Firm Shares set forth opposite the
name of each remaining non-defaulting Underwriter in SCHEDULE 1 hereto bears to
the total number of shares of the Firm Shares set forth opposite the names of
all the remaining non-defaulting Underwriters in SCHEDULE 1 hereto; provided,
however, that the remaining non-defaulting Underwriters shall not be obligated
to purchase any of the Shares on such Delivery Date if the total number of
Shares which the defaulting Underwriter or Underwriters agreed but failed to
purchase on such date exceeds 9.09% of the total number of Shares to be
purchased on such Delivery Date, and any remaining non-defaulting Underwriter
shall not be obligated to purchase more than 110% of the number of Shares which
it agreed to purchase on such Delivery Date pursuant to the terms of Section 3.
If the foregoing maximums are exceeded, the remaining non-defaulting
Underwriters, or those other underwriters satisfactory to the Representatives
who so agree, shall have the right, but shall not be obligated, to purchase, in
such proportion as may be agreed upon among them, all the Shares to be purchased
on such Delivery Date. If the remaining Underwriters or other underwriters
satisfactory to the Representatives do not elect to purchase the Shares which
the defaulting Underwriter or Underwriters agreed but failed to purchase on such
Delivery Date, this Agreement shall terminate without liability on the part of
any non-defaulting Underwriter or the Company or the Selling Stockholders,
except that the Company, the Selling Stockholders and the Underwriters will
continue to be liable for the payment of expenses to the extent set forth in
Sections 8 and 13. As used in this Agreement, the term "UNDERWRITER" includes
(along with the parties mentioned in SCHEDULE 1), for all purposes of this
Agreement unless the context requires otherwise, any party not listed in
SCHEDULE 1 hereto who, pursuant to this Section 11, purchases Shares that a
defaulting Underwriter agreed but failed to purchase.

Nothing contained herein shall relieve a defaulting Underwriter of any liability
it may have to the Company and the Selling Stockholders for damages caused by
its default. If other underwriters are obligated or agree to purchase the Shares
of a defaulting Underwriter, either the Representatives or the Company may
postpone the Delivery Date for up to seven full business days in order to effect
any changes in the opinion of counsel for the Company or counsel for the
Underwriters that may be necessary in the Registration Statement, the Prospectus
or in any other document or arrangement.

                                       33
<Page>

     SECTION 12.  TERMINATION. The obligations of the Underwriters hereunder
may be terminated by the Representatives by notice given to and received by the
Company prior to delivery of and payment for the Firm Shares if, prior to that
time, any of the events described in Sections 9(l) or 9(m), shall have occurred
such that the conditions set forth in such Sections shall not be satisfied, or
if the Underwriters shall decline to purchase the Shares for any reason
permitted under this Agreement.

     SECTION 13.  REIMBURSEMENT OF UNDERWRITERS' EXPENSES. If the Company or
any Selling Stockholder shall fail to tender the Shares for delivery to the
Underwriters by reason of any failure, refusal or inability on the part of the
Company or such Selling Stockholder to perform any agreement on its part to be
performed, or because any other condition of the Underwriters' obligations
hereunder required to be fulfilled by the Company or such Selling Stockholder
(including, without limitation, with respect to the Transactions) is not
fulfilled, the Company or such Selling Stockholder, as the case may be, will
reimburse the Underwriters for all reasonable out-of-pocket expenses (including
fees and disbursements of counsel) incurred by the Underwriters in connection
with this Agreement and the proposed purchase of the Shares, and upon demand
after the provision by the Representatives of reasonable documentation thereof,
the Company or such Selling Stockholder, as the case may be, shall pay the full
amount thereof to the Representatives, provided that if both the Company and
such Selling Stockholder shall have failed to tender the Shares for delivery,
such payment shall be made pro rata based upon the number of Shares to be sold
by such party. If this Agreement is terminated pursuant to Section 11 by reason
of the default of one or more Underwriters, neither the Company nor any Selling
Stockholder shall be obligated to reimburse any defaulting Underwriter on
account of those expenses.

     SECTION 14.  NOTICES, ETC. All statements, requests, notices and
agreements hereunder shall be in writing, and:

          (a)     if to the Underwriters, shall be delivered or sent by mail,
telex or facsimile transmission (with confirmation of transmission) to Lehman
Brothers Inc., 745 Seventh Avenue, 19th Floor, New York, New York 10019,
Attention: Syndicate Registration (Fax: (646) 497-4815), with a copy, in the
case of any notice pursuant to Section 10(d), to the Director of Litigation,
Office of the General Counsel, Lehman Brothers Inc., 399 Park Avenue, 10th
Floor, New York, NY 10022 (Fax: (212) 520-0421), and with a copy to Wilson
Sonsini Goodrich & Rosati, Professional Corporation, 650 Page Mill Road, Palo
Alto, California, 94304, Attention: Matthew W. Sonsini (Fax: (650) 493-6811);

          (b)     if to the Company, shall be delivered or sent by mail or
facsimile transmission (with confirmation of transmission) to the address of the
Company set forth in the Registration Statement, Attention: President and Chief
Executive Officer (Fax: (978) 250-3373), with a copy to Foley Hoag LLP, World
Trade Center West, 155 Seaport Boulevard, Boston, Massachusetts 02210, Attention
Robert W. Sweet, Jr. (Fax: (617) 832-7000);

                                       34
<Page>

          (c)     if to any Selling Stockholder, shall be delivered or sent by
mail or facsimile transmission (with confirmation of transmission) to such
Selling Stockholder at the address set forth on SCHEDULE 2 hereto;

          (d)     provided, however, that any notice to an Underwriter pursuant
to Section 10(d) shall be delivered or sent by mail, telex or facsimile
transmission to such Underwriter at its address set forth in its acceptance
telex to the Representatives, which address will be supplied to any other party
hereto by the Representatives upon request. Any such statements, requests,
notices or agreements shall take effect at the time of receipt thereof. The
Company shall be entitled to act and rely upon any request, consent, notice or
agreement given or made on behalf of the Underwriters or the Representatives by
Lehman Brothers Inc.

          (e)     The Underwriters, the Company and any Selling Stockholder may
change the address for delivery of notice (including telex and facsimile
numbers) by giving notice thereof to the other parties.

     SECTION 15.  PERSONS ENTITLED TO BENEFIT OF AGREEMENT. This Agreement
shall inure to the benefit of and be binding upon the Underwriters, the Company,
the Selling Stockholders and their respective successors, heirs, executors,
administrators and legal representatives. This Agreement and the terms and
provisions hereof are for the sole benefit of only those persons, except that
(a) the representations, warranties, indemnities and agreements of the Company
and the Selling Stockholders contained in this Agreement shall also be deemed to
be for the benefit of directors, officers, employees, agents of the Underwriters
and the person or persons, if any, who control any Underwriter within the
meaning of Section 15 of the Securities Act and (b) the indemnity agreement of
the Underwriters contained in Section 10(c) of this Agreement shall be deemed to
be for the benefit of directors of the Company, officers of the Company who have
signed the Registration Statement, the Selling Stockholders and any person
controlling the Company or any Selling Stockholder within the meaning of Section
15 of the Securities Act. Nothing in this Agreement is intended or shall be
construed to give any person, other than the persons referred to in this Section
15, any legal or equitable right, remedy or claim under or in respect of this
Agreement or any provision contained herein.

     SECTION 16. NO FIDUCIARY DUTY. Notwithstanding any preexisting relationship
, advisory or otherwise, between the parties or any oral representations or
assurances previously or subsequently made by the Underwriters, the Company and
the Selling Stockholders acknowledge and agree that in connection with the
offering: (a) there exists no fiduciary or agency relationship between the
Company or Selling Stockholders, on the one hand, and the Underwriters, on the
other; (b) the relationship between the Company and the Selling Stockholders, on
the one hand, and the Underwriters, on the other, is entirely and solely
commercial, based on arms-length negotiations, and the Underwriters are not
acting as advisors, expert or otherwise, to either the Company or the Selling
Stockholders; (c) notwithstanding anything in this Agreement to the contrary,
the Company and the Selling Stockholders acknowledge that

                                       35
<Page>

the Underwriters may have financial interests in connection with the offering in
addition to the difference between the price to the public and the purchase
price paid to the Company and the Selling Stockholders, respectively, by the
Underwriters for the shares, and the Underwriters have no obligation to
disclose, or account to the Company or the Selling Stockholders for, any of such
additional financial interests. The Company and the Selling Stockholders hereby
waive and release, to the fullest extent permitted by law, any claims that the
Company or the Selling Stockholders may have against the Underwriters with
respect to any breach or alleged breach of fiduciary duty in connection with the
Transactions.

     SECTION 17.  SURVIVAL. The respective indemnities, representations,
warranties and agreements of the Company, the Selling Stockholders and the
Underwriters contained in this Agreement or made by or on behalf on them,
respectively, pursuant to this Agreement, shall survive the delivery of and
payment for the Shares and shall remain in full force and effect, regardless of
any investigation made by or on behalf of any of them or any person controlling
any of them.

     SECTION 18.  DEFINITION OF THE TERMS "BUSINESS DAY" AND "SUBSIDIARY".
For purposes of this Agreement, (a) "BUSINESS DAY" means each Monday, Tuesday,
Wednesday, Thursday or Friday which is not a day on which banking institutions
in New York are generally authorized or obligated by law or executive order to
close and (b) "SUBSIDIARY" has the meaning set forth in Rule 405 of the Rules
and Regulations.

     SECTION 19.  GOVERNING LAW. This Agreement shall be governed by and
construed in accordance with the laws of New York.

     SECTION 20.  COUNTERPARTS. This Agreement may be executed in one or
more counterparts and, if executed in more than one counterpart, the executed
counterparts shall each be deemed to be an original but all such counterparts
shall together constitute one and the same instrument.

     SECTION 21.  HEADINGS. The headings herein are inserted for convenience
of reference only and are not intended to be part of, or to affect the meaning
or interpretation of, this Agreement.

                            [SIGNATURE PAGE FOLLOWS]

                                       36
<Page>

If the foregoing correctly sets forth the agreement among the Company, the
Selling Stockholders and the Underwriters, please indicate your acceptance in
the space provided for that purpose below.

                                   Very truly yours,

                                   HITTITE MICROWAVE CORPORATION

                                   By:
                                       -----------------------------------------
                                   Name:
                                         ---------------------------------------
                                   Title:
                                          --------------------------------------

                                   THE SELLING STOCKHOLDERS LISTED IN SCHEDULE 2
                                   TO THE AGREEMENT

                                   By:
                                      ------------------------------------------
                                       Attorney-in-Fact

Accepted:

LEHMAN BROTHERS INC.
NEEDHAM & COMPANY, LLC
PIPER JAFFRAY & CO.
THOMAS WEISEL PARTNERS LLC

For themselves and as Representatives
of the several Underwriters listed
in Schedule 1 hereto

By: LEHMAN BROTHERS INC.

By:
    -----------------------------------------
Name:
      ---------------------------------------
Title:
       --------------------------------------

<Page>

                                   SCHEDULE 1

<Table>
<Caption>
                                                         NUMBER OF SHARES OF
                                                           FIRM SHARES TO BE
UNDERWRITER                                                        PURCHASED
----------------------------------------------------------------------------
<S>                                                                <C>
Lehman Brothers Inc.                                               1,935,000
Needham & Company, LLC                                               788,334
Piper Jaffray & Co.                                                  788,333
Thomas Weisel Partners LLC                                           788,333
Chatsworth Securities LLC                                             50,000
National Financial Markets Group, a Division
   of National Financial Services LLC                                 50,000
Oppenheimer & Co. Inc.                                                50,000
Raymond James & Associates, Inc.                                      50,000
                                       TOTAL                       4,500,000
</Table>

<Page>

                                   SCHEDULE 2

<Table>
<Caption>
     NAME OF SELLING
STOCKHOLDER AND ADDRESS(1)                      FIRM SHARES TO BE SOLD
----------------------------------------------------------------------
<S>                                                      <C>
Summit Ventures V, L.P.                                  543,863
222 Berkeley Street, 18th Floor
Boston, Massachusetts, 02116

Summit V Companion Fund, L.P.                            187,369
222 Berkeley Street, 18th Floor
Boston, Massachusetts, 02116

Summit V Advisors                                         41,903
Fund (QP), L.P.
222 Berkeley Street, 18th Floor
Boston, Massachusetts, 02116

Summit V Advisors Fund, L.P.                              12,805
222 Berkeley Street, 18th Floor
Boston, Massachusetts, 02116

Summit Investors III, L.P.                                14,060
222 Berkeley Street, 18th Floor
Boston, Massachusetts, 02116

Dr. S. Francis Paik                                      277,778
16 Minebrook Road
Lincoln, MA 01773

George F. Paik Irrevocable Trust                         222,222
15 Overlook Drive
Newtown, CT 06470

Richard A. Paik Irrevocable Trust                        277,778
13 Commonwealth Avenue
Swampscott, MA 01907

Carol A. Paik Irrevocable Trust                          222,222
670 West End Avenue
New York, NY 10025

                            TOTAL                      1,800,000
</Table>

(1). Each Selling Stockholder has appointed Stephen G. Daly and William W.
Boecke, and each of them, as Attorneys-in-Fact for such Selling Stockholder.

<Page>

                                    EXHIBIT A

 Form of Opinion of Iandiorio & Teska, Intellectual Property Counsel for Company

                                                  , 2005

LEHMAN BROTHERS INC.
NEEDHAM & COMPANY, LLC
PIPER JAFFRAY & CO.
THOMAS WEISEL PARTNERS LLC
     As Representatives of the several
     Underwriters
c/o Lehman Brothers Inc.
745 Seventh Avenue
New York, New York 10019

              Re: Intellectual Property of Hittite Microwave Corp.
                  Our reference No.: HIT-100J

Ladies and Gentlemen:

           We have been retained by Hittite Microwave Corp. (the "Company") with
respect to its intellectual property matters, including its patent matters. We
have been asked by the Company to provide an opinion concerning its patents.

           The status of the Company's patents and patent applications, as of
April 20, 2005, is shown in Exhibit A attached hereto. As indicated therein, the
Company has 9 issued U.S. patents, 1 pending U.S. patent applications, 2 issued
foreign patents and 0 pending foreign patent applications.

           Exhibit A to this opinion is a list of the Company's patents and
pending patent applications (the "Patent Rights") which, to the best of our
knowledge, are owned by the Company. To the best of our knowledge either (a) an
assignment from the inventor(s) to the Company has been recorded in the United
States Patent and Trademark Office or in other applicable foreign jurisdictions,
or (b) the inventor(s) are under obligation of assignment to the Company, and an
assignment will be recorded in the United States Patent and Trademark Office or
in other applicable foreign jurisdictions. To the best of our knowledge, there
are no claims to any ownership interests or liens on any of the Patent Rights by
any party other than the Company. To the best of our knowledge, the Company has
not licensed the rights to use any of its patents.

           We are unaware of any facts that would lead us to believe that: (a)
any of the patents, which are listed in Exhibit A of this opinion, are invalid,
(b) any patent that may be issued in respect of a patent application, which is
listed in Exhibit A of this opinion, would be invalid, or

<Page>

(c) any material defects of form exist in the preparation or filing of any of
the patents and patent applications which are listed in Exhibit A of this
opinion.

           To the best of our knowledge, for each of the U.S. patent
applications filed and prosecuted by us reflected in Exhibit A, we have
disclosed or intend to disclose to the United States Patent and Trademark Office
all information known to us and believed by us to be material to patentability
as required under 37 C.F.R. Section 1.56.

           To the best of our knowledge, there are no pending or threatened
legal or governmental proceedings relating to the patents and pending patent
applications reflected in Exhibit A, other than the proceedings before the
United States Patent and Trademark Office and foreign patent offices that are
carried out during the course of prosecution.

           Other than any other actions, suits, proceedings or claims that have
been resolved or are immaterial, to the best of our knowledge the Company has
not received any claim of infringement of any patents held by others, and to our
knowledge there is no pending or threatened action, suit, proceeding or claim by
others that the Company is infringing a patent.

           In addition, other than any actions, suits, proceedings or claims
that have been resolved, nothing has come to our attention that has led us to
believe that any patents of others are infringed by the present or future
business of the Company as described in the Prospectus under the caption
"Business." We have read the portions of the Prospectus under the captions "Risk
Factors - Claims that we are infringing third-party intellectual property rights
may result in costly and lengthy litigation that could harm our business", "Risk
Factors -We use a number of specialized technologies, some of which are
patented, to design, develop and manufacture our products. Infringement of our
intellectual property rights could hurt our competitive position, harm our
reputation and adversely affect our results of operations," "Business -
Intellectual Property" and "Business -Litigation." We have considered the
statements contained therein, although we have not independently verified the
accuracy, completeness and fairness of such statements. Based upon and subject
to the foregoing, nothing has come to our attention, as of the date of the
Prospectus and the date hereof, that leads us to believe that the Patent
Information contains an untrue statement of a material fact or omits to state a
material fact in light of the circumstances in which they are made. As of the
date of the Prospectus and the date hereof, we have no reason to believe that
the Patent Information is not in all material respects a fair and accurate
summary of the legal matters, documents and proceedings relating thereto,
insofar as such statements constitute a summary of the Company's patents and
applications and legal proceedings related thereto.

           As used in this letter, "to the best of our knowledge" means this
firm's current knowledge, based upon information received from the Company, as a
consequence of our representation of the Company, and upon the patent
applications filed and prosecuted by us on behalf of the Company. With respect
to ownership of the United States patents, our opinion is based upon our
"knowledge" and upon our review of the United States Patent and Trademark Office
assignee records.

           The statements in this letter with respect to patent infringement and
validity should be understood to involve a complex area of law where reasonable
minds, including those of judges

<Page>

or juries, differ. It should be understood that the opinion set forth above is
as of the date hereof and is not intended as a guarantee of any particular
result or decision.

           We assume no obligation to advise you of any changes to the foregoing
subsequent to the delivery of this letter. Please also note that this opinion is
provided to you only for the specific purpose of assisting you in your
confidential evaluation of the Company. This opinion is not provided for any
other purpose, and you should not provide this opinion or disclose its contents
to any third party without obtaining our prior approval.

                                                    Very truly yours,

<Page>

                                    EXHIBIT B

               Form of Opinion of Counsel for Selling Stockholders

     (i)    Each Selling Stockholder has record ownership of the number of
shares of Common Stock or Series A Preferred Stock set forth opposite the name
of such Selling Stockholder on EXHIBIT A hereto, which shares are represented by
the certificates identified on EXHIBIT A hereto. To our knowledge, each Selling
Stockholder has full power and authority to sell, transfer and deliver the
Shares to be sold by such Selling Stockholder pursuant to the Underwriting
Agreement. Assuming that the Underwriters do not have notice of any adverse
claim (within the meaning of Sections 8-102(a)(1) and 8-105 of the New York
Uniform Commercial Code) to the Shares to be sold by such Selling Stockholder,
upon delivery to the Underwriters of the certificates for such Shares by or on
behalf of such Selling Stockholder duly indorsed in blank or accompanied by duly
executed stock powers in favor of the Underwriters and all applicable stock
transfer stamps against payment therefor as provided in the Underwriting
Agreement, the Underwriters will acquire such Shares free of any adverse claim
(within the meaning of Section 8-102(a)(1) of the New York Uniform Commercial
Code);

     (ii)   Except for the registration of the Shares under the Securities Act
and such consents, approvals, authorizations, orders, filings, registrations or
qualifications as may be required under the Exchange Act, applicable state or
foreign securities laws in connection with the purchase and distribution of the
Shares by the Underwriters, the rules of the Nasdaq Stock Market, Inc. and the
rules of the NASD, to the knowledge of such counsel, no consent, approval,
authorization or order of, or filing with, any federal or Massachusetts court or
governmental agency or body is required for the consummation by each Selling
Stockholder of the transactions contemplated by the Underwriting Agreement,
except for such consents, approvals, authorizations, orders, filings,
registrations or qualifications as have been obtained or made;

     (iii)  The execution, delivery and performance by each Selling Stockholder
of the Underwriting Agreement and the consummation by each Selling Stockholder
of the transactions contemplated thereby will not result in a violation of the
charter or by-laws of such Selling Stockholder, if applicable, or any material
violation of any statute, order, rule or regulation known to such counsel of any
federal or Massachusetts court or governmental agency or body having
jurisdiction over such Selling Stockholder or any of its properties;

     (iv)   Each of the Power of Attorney and the Custody Agreement of each
Selling Stockholder has been duly authorized, executed and delivered by such
Selling Stockholder and constitutes a valid and legally binding obligation of
such Selling Stockholder, enforceable against such Selling Stockholder in
accordance with its terms, subject to bankruptcy, insolvency, fraudulent
transfer, reorganization, moratorium and similar laws of general applicability
relating to or affecting creditors' rights and to general equity principles; and

     (v)    The Underwriting Agreement has been duly authorized by each Selling
Stockholder (other than any Selling Stockholder that is an individual) and has
been duly executed and delivered by the Attorneys on behalf of each Selling
Stockholder.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00088-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00088-of-00352.parquet"}]]